

Consensus statement

**Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)**

*Coordinators (by alphabetical order):*

Fernando Chaves <sup>a</sup>, José Garnacho-Montero <sup>b</sup>, and José Luis del Pozo <sup>c,\*</sup>

<sup>a</sup> Servicio de Microbiología, Hospital Universitario 12 de Octubre, Madrid

<sup>b</sup> Unidad Clínica de Cuidados Intensivos, Hospital Universitario Virgen Macarena, Sevilla

<sup>c</sup> Área de Enfermedades Infecciosas, Servicio de Microbiología, Clínica Universidad de Navarra, Pamplona

*Authors (by alphabetical order):*

Emilio Bouza <sup>a</sup>, José Antonio Capdevila <sup>b</sup>, Marina de Cueto <sup>c</sup>, M.<sup>a</sup> Ángeles Domínguez <sup>d</sup>, Jaime Esteban <sup>e</sup>, Nuria Fernández-Hidalgo <sup>f</sup>, Marta Fernández Sampedro <sup>g</sup>, Jesús Fortún <sup>h</sup>, María Guembe <sup>i</sup>, Leonardo Lorente <sup>j</sup>, Jose Ramón Paño <sup>k</sup>, Paula Ramírez <sup>l</sup>, Miguel Salavert <sup>m</sup>, Miguel Sánchez <sup>n</sup>, and Jordi Vallés <sup>o</sup>

<sup>a</sup> Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid; CIBER de Enfermedades Respiratorias, CibeRes, Instituto de Salud Carlos III, Madrid; Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid

<sup>b</sup> Servicio de Medicina Interna, Hospital de Mataró, Mataró, Barcelona

<sup>c</sup> *Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla*

<sup>d</sup> *Servicio de Microbiología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona*

<sup>e</sup> *Departamento de Microbiología Clínica, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid*

<sup>f</sup> *Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona*

<sup>g</sup> *Servicio de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Santander*

<sup>h</sup> *Unidad de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid*

<sup>i</sup> *Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid*

<sup>j</sup> *Unidad de Cuidados Intensivos, Hospital Universitario de Canarias, Santa Cruz de Tenerife*

<sup>k</sup> *Unidad de Enfermedades Infecciosas, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza*

<sup>l</sup> *Unidad de Cuidados Intensivos, Hospital Universitari i Politècnic La Fe, Valencia ; CIBER de Enfermedades Respiratorias (CibeRes), Instituto de Salud Carlos III, Madrid*

<sup>m</sup> *Unidad de Enfermedades Infecciosas, Hospital Universitari i Politècnic La Fe, Valencia*

<sup>n</sup> *Servicio de Medicina Intensiva, Hospital Clínico San Carlos, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid*

<sup>o</sup> *Unidad de Cuidados Intensivos, Hospital Universitari Parc Taulí, Sabadell, Barcelona; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid*

## ABSTRACT

Catheter-related bloodstream infections (CRBSI) constitute an important cause of hospital-acquired infection associated with morbidity, mortality, and cost. The aim of these guidelines is to provide updated recommendations for the diagnosis and management of CRBSI in adults. Prevention of CRBSI is excluded. Experts in the field were designated by the two participating Societies (the Spanish Society of Infectious Diseases and Clinical Microbiology and [SEIMC] and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units [SEMICYUC]). Short-term peripheral venous catheters, non-tunneled and long-term central venous catheters, tunneled catheters and hemodialysis catheters are covered by these guidelines. The panel identified 39 key topics that were formulated in accordance with the PICO format. The strength of the recommendations and quality of the evidence were graded in accordance with ESCMID guidelines. Recommendations are made for the diagnosis of CRBSI with and without catheter removal and of tunnel infection. The document establishes the clinical situations in which a conservative diagnosis of CRBSI (diagnosis without catheter removal) is feasible. Recommendations are also made regarding empirical therapy, pathogen-specific treatment (coagulase-negative staphylococci, *Staphylococcus aureus*, *Enterococcus* spp., Gram-negative bacilli, and *Candida* spp.), antibiotic lock therapy, diagnosis and management of suppurative thrombophlebitis and local complications.

## ARTICLE INFORMATION

### **Keywords:**

Catheter-related bloodstream infection

Guidelines

Bacteremia

Blood cultures

Antibiotic

## **Diagnóstico y tratamiento de la bacteriemia relacionada con catéter: guía de práctica clínica de la Sociedad Española de Enfermedades Infecciosas**

## **y Microbiología Clínica (SEIMC) y de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)**

### **RESUMEN**

La bacteriemia relacionada con catéteres (BRC) es una causa importante de infección hospitalaria y se asocia con elevados morbilidad, mortalidad y costes. El objetivo de esta guía de práctica clínica es proporcionar recomendaciones actualizadas para el diagnóstico y tratamiento de la BRC en pacientes adultos. De este documento se excluye la prevención de la BRC. Expertos en la materia fueron designados por las dos Sociedades participantes (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica y Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias). Los catéteres venosos periféricos a corto plazo, los catéteres venosos centrales no tunelizados y de largo plazo, los catéteres tunelizados y los catéteres de hemodiálisis están incluidos en estas guías. El panel identificó 39 temas clave que fueron formulados de acuerdo con el formato PICO. La fuerza de las recomendaciones y la calidad de la evidencia se clasificaron de acuerdo con las directrices de la ESCMID. Se dan recomendaciones para el diagnóstico de BRC con extracción de catéter y sin él, y de la infección en túnel. El documento establece las situaciones clínicas en que es factible un diagnóstico conservador de CRBSI (diagnóstico sin retirada de catéter). También se dan recomendaciones respecto a la terapia empírica, el tratamiento específico según el patógeno identificado (estafilococos coagulasa-negativos, *Staphylococcus aureus*, *Enterococcus* spp., bacilos gramnegativos y *Candida* spp.), la terapia con sellado del catéter y el diagnóstico, así como tratamiento de la tromboflebitis supurativa y las complicaciones locales.

#### **Palabras clave:**

Bacteriemia relacionada con catéter

Guía de práctica clínica

Bacteriemia

Hemocultivos

Antibioticoterapia

\*Corresponding autor.

José Luis del Pozo

*E-mail:* jdelpozo@unav.es

## **Introduction: Justification and aims**

Intravascular devices have become an essential component of modern medicine for the administration of intravenous fluids, medication, blood products and parenteral nutrition and for monitoring hemodynamic status and providing hemodialysis. According to national data supplied by the study of the prevalence of nosocomial infections in Spain (EPINE), it is estimated that about 70% of patients admitted to Spanish hospitals will wear one of these devices at some point during their stay<sup>1</sup>. Local or systemic infections represent one of the main associated complications<sup>2</sup>. The incidence of catheter-related infections varies considerably depending on the type and intended use, the insertion site, the experience and training of the individual who places the catheter, the frequency with which the catheter is accessed, duration of catheter placement, the characteristics of the patient, and the use of proven prevention strategies. Catheter-related bloodstream infections (CRBSIs) are among the most frequent infections acquired in hospital. Current estimates are that between 15% and 30% of all nosocomial bacteraemias are catheter-related<sup>3</sup>. CRBSIs have significant associated morbidity, incur increased hospital costs<sup>4</sup>, estimated at approximately 18,000 euros per episode, and length of stay<sup>5</sup>. Attributable mortality ranges between 12% and 25%<sup>6</sup>. In recent years, there has been a remarkable increase in our knowledge of the epidemiology of CRBSI and of the most appropriate methodologies for diagnosis, management and prevention. The vast amount of information accumulated and the inherent complexity of this type of infection make it necessary to sort and analyze the available information. At the same time, there are few current guidelines available on this topic. The last Spanish catheter-related infections guidelines were published in 2004<sup>7</sup>. The aim of this new guide is to update recommendations for the diagnosis and management of catheter-related bloodstream infections. This

document targets only microbiological diagnosis and antimicrobial therapy; other aspects of infection management and prevention are therefore excluded. Only adult patients with these infections are covered.

## Methods

The two participating Societies (the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica and the Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias) nominated three coordinators for this project (FC, JGM and JLdP: a microbiologist, an intensivist, and an infectious disease physician). This coordinating group selected the rest of the members of the panel, including microbiologists, intensivists, and infectious disease physicians. The Scientific Committees of both Societies approved their proposal. The present Statement was written following the SEIMC guidelines for consensus statements ([www.seimc.org](http://www.seimc.org)) as well as the recommendations of the Agree Collaboration ([www.agreecollaboration.org](http://www.agreecollaboration.org)) for evaluating the methodological quality of clinical practice guidelines. The strength of the recommendations and quality of the evidence were graded in accordance with ESCMID guidelines (Table 1).

The coordinating group identified 39 key topics that were formulated in accordance with the PICO format defining the population, intervention, comparator, and outcome of interest. These key questions were approved by the Scientific Committees of both Societies and then distributed to the different members of the panel (2 or 3 questions each) for further development. The coordinating group wrote the first draft based on the sections submitted by each participant, which was then sent to the panel for critical review. Before its final approval, the document was published on the intranet of both Societies and left open to suggestions and comments from members. All authors and coordinators of the Statement have agreed the contents of the document and the final recommendations. A summary of these recommendations is available in the Supplementary Electronic Material.

### **Catheter-related bloodstream infection diagnosis (Table 2)**

## General aspects

### *When should catheter-related bloodstream infection be suspected?*

CRBSI should be clinically suspected if the patient has fever, chills or hypotension with signs of infection proximal to insertion sites of peripheral venous cannulae or on the skin overlying the subcutaneous tunnel of a tunneled catheter<sup>8</sup>. Several circumstances should increase suspicion that a given episode of bacteremia is catheter-related. The most obvious one is a patient with local signs of infection at the catheter. In addition, bloodstream infections are often caused by microorganisms that colonize the skin, such as *Staphylococcus aureus*, coagulase-negative staphylococci, *Corynebacterium* spp., *Bacillus* spp., *Candida* spp., among others. CRBSI should also be considered in settings of persistent or recurrent blood cultures for given microorganisms<sup>8</sup>. Clinical suspicion of CRBSI should also arise in patients with intravenous catheters who have focal infections known to be caused by the hematogenous spread of bacteria (i.e., septic emboli); this is the case in endocarditis or suppurative thrombophlebitis, particularly if caused by *Staphylococcus* spp. or *Candida* spp. in patients with venous catheters. Septic emboli secondary to a CRBSI are more frequently found in the lungs<sup>9</sup>, although virtually any organ can be affected by septic metastasis arising from an infected catheter<sup>10,11</sup>.

## RECOMMENDATIONS

1. CRBSI should be suspected in patients with intravenous catheters and fever, chills or other signs of sepsis, even in the absence of local signs of infection, and especially if no alternative source is identified (A-III).
2. Clinical suspicion of CRBSI should also arise in patients with intravenous catheters with metastatic infections caused by hematogenous spread of microorganisms (i.e., septic emboli) (A-III).
3. Persistent or recurrent bacteremia caused by microorganisms that colonize the skin in patients with intravenous catheters should lead to CRBSI suspicion (A-III).

### *How is complicated catheter-related bloodstream infection defined?*

There are several factors associated with worse outcomes in patients with CRBSI and identifying these risk factors can help in the management of those patients. There is no universally accepted definition of complicated CRBSI. Endocarditis is one of the main CRBSI-associated complications with a prolonged therapy that requires catheter removal. Suppurative thrombophlebitis also makes CRBSI complicated, as do metastatic foci of infection, which usually require prolonged therapy and catheter removal. Local complications, such as tunnel infection or a port abscess, even in the absence of septic thrombophlebitis, require catheter removal and so complicate a CRBSI<sup>10,11</sup>. Systemic severity (septic shock) in patients with suspected CRBSI is another circumstance that should lead to prompt catheter removal. Non-resolving fever or bacteremia ( $\geq 72$  hours) should lead to a detailed reassessment of the patient in order to rule out local or distant infectious complications and so should be considered complicated CRBSI. It is very important to closely monitor immunocompromised hosts with CRBSI for possible treatment failure.

#### **RECOMMENDATIONS**

1. Patients diagnosed with CRBSI and with endocarditis, suppurative thrombophlebitis, septic metastasis, extraluminal infections, septic shock, non-resolving CRBSI, or immunocompromised patients should be categorized as complicated CRBSI (A-III).
2. Non-resolving fever or bacteremia ( $\geq 72$  hours) should lead to a detailed reassessment of the patient in order to rule out local or distant infectious complications and so should be considered complicated CRBSI (A-III).

#### **Diagnosis without catheter withdrawal (conservative diagnosis)**

##### *How should blood cultures be taken?*

Because the aim of a blood culture is to detect true bacteremia and avoid contamination leading to unnecessary treatment, a proper diagnostic methodology is needed. This is particularly important when catheter-related bacteremia is suspected, because the common etiologic agents are also the most frequent contaminants.

Conventional blood cultures are currently performed using commercial systems with automated detection of growth. These systems consist of an aerobic and an anaerobic bottle, considered as one blood culture set. Some studies show a sensitivity of <80% for one blood culture set and >99% for 3 or more culture sets<sup>12–14</sup>. To ensure optimal detection of bacteremia, the volume of blood is the essential factor. The Clinical and Laboratory Standards Institute (CLSI) recommends therefore that a blood volume of at least 20 ml be inoculated into each of 2 blood culture sets (two bottles per set) taken from different venipuncture sites<sup>15</sup>.

Blood must be obtained using an aseptic methodology to reduce the risk of contamination<sup>16–18</sup> to less than 3% of all blood culture sets<sup>19</sup>, which is considered to be the acceptable range. The venipuncture should be performed after disinfecting the skin. The three key factors when choosing the antiseptic are: antimicrobial spectrum, method of application, and duration of antimicrobial effect. The most commonly used disinfectants are alcohol-, chlorhexidine- and iodine-based products<sup>20–24</sup>. A recent meta-analysis of 6 randomized control trials concluded that: 1) overall, alcohol-based products seemed to be superior to non-alcohol-based solutions, and 2) solutions containing a combination of alcohol and chlorhexidine showed significant reductions in contaminated blood cultures compared with aqueous povidone-iodine<sup>23</sup>. The most widely studied concentration is 2% chlorhexidine gluconate in isopropyl alcohol. On the other hand, a recent study showed that choice of antiseptic agent did not impact contamination rates when the blood cultures were collected by a phlebotomy team. Perhaps the single most important aspect is the use of proper technique, which includes time required to perform the procedure and allowing enough time for the disinfectant to exert its antimicrobial effect. Alcohol and chlorhexidine products require 30 seconds to dry, whereas povidone iodine preparations require 1.5–2 minutes. No studies have evaluated the effect of disinfecting catheter access hubs before drawing the blood samples<sup>16</sup>, although it seems to be a rational intervention aimed at minimizing risk of contamination.

The timing of blood culture collection may vary. Although most blood culture systems have different methods of minimizing the effect of antibiotics<sup>25,26</sup>, the samples should be obtained, if at all possible, before antibiotic therapy is started<sup>16,25–27</sup>. Blood cultures obtained from intravascular

catheters are associated with higher sensitivity and negative predictive values<sup>17</sup>. In patients with suspected CRBSI, two sets of blood cultures should be taken, one from a peripheral vein and the other from the catheter hub. For multiple-lumen venous catheters, several studies suggest that blood cultures be drawn from all lumens (i.e., the same volume from each lumen) to establish a diagnosis of CRBSI. Omitting a culture of samples from one or more lumens is associated with failing to detect a considerable number of CRBSI episodes<sup>28–30</sup>.

Once drawn, the blood should be immediately inoculated into the blood culture bottles, which should then be appropriately marked (peripheral vein, catheter, etc.) and promptly and simultaneously incubated in the automated machine, in order to interpret the results on the basis of time to positivity of each blood culture set. Because the rubber caps are not sterile, they are usually disinfected with an alcohol solution, which must be dried before inoculation. Since the incidence of true anaerobic bacteraemia is low<sup>31</sup>, it may be preferable to inoculate the optimal volume of blood into the aerobic bottle first, and then the remaining volume into the anaerobic bottle.

## RECOMMENDATIONS

1. Blood cultures should be obtained using an aseptic technique and before the initiation of antimicrobial therapy (A-I).
2. Skin preparation for obtaining blood samples drawn percutaneously should be performed with proper techniques, including the time to perform the procedure and leaving adequate time for the disinfectant to take effect (A-I). Alcohol-containing products are associated with low rates of contamination. Alcohol-chlorhexidine solutions reduce blood culture contamination more efficiently than aqueous povidone-iodine (A-I).
3. Two pairs of blood cultures should be drawn in patients with suspected CRBSI, one from a peripheral vein and the other from the catheter (A-I).
4. For multiple-lumen venous catheters, samples should be obtained from all lumens (A-II).

*How should conventional blood cultures be interpreted?*

Identification of the microorganism is considered crucial for interpreting the significance of the result. *Propionibacterium* spp., *Bacillus* spp., and most *Corynebacterium* spp. almost always mean contamination<sup>16,26,32</sup>. Contamination is defined as the isolation of an organism in a blood culture that is not present in the patient's bloodstream<sup>19</sup>. Unfortunately, some of the microorganisms that frequently contaminate blood cultures are also common causes of CRBSI, such as coagulase-negative staphylococci, which is the leading cause of CRBSI. Other organisms that cause bacteremia, such as *S. aureus* and *Enterococcus* spp., can also be detected as contaminants, albeit in a low percentage of cases<sup>33</sup>. In the case of skin commensals, at least 2 positive blood cultures with an identical strain are required for them to be considered a cause of bacteremia<sup>25</sup>.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is one of the most widely evaluated new technologies for the rapid microbial identification of blood culture isolates<sup>34-40</sup>. Although the performance of MALDI-TOF-based identification varies depending on the enrichment and purification methods used, this technology has shown high sensitivity and specificity for rapid identification of microbes in positive blood cultures<sup>34-40</sup>. MALDI-TOF has some limitations associated with the identification of some Gram-positive microorganisms (*Streptococcus* spp.), non-fermenting Gram-negatives, and non-albicans *Candida* species<sup>39</sup>, although its use in the clinical setting could improve time to identification of microorganisms, time to effective therapy and time to optimal antimicrobial therapy<sup>41</sup>.

Detecting the actual time to positivity of each blood culture is considered critical to the diagnosis of CRBSI. Several studies have confirmed that measuring the differential time to positivity (DTP) of blood cultures obtained from a central venous catheter and a peripheral vein is highly diagnostic for suspected CRBSI<sup>42,43</sup>. Blot et al.<sup>44,45</sup> reported that a DTP cut-off limit of 120 minutes had 94% sensitivity and 94% specificity for catheter-related infection, and 96.4% sensitivity and 100% specificity for catheter-related sepsis. Other studies showed similar results for the same cut-off value, with sensitivities ranging from 72% to 96.4% and specificities between 90.3% and 95%<sup>42,43</sup>. Raad et al.<sup>46</sup> showed that a DTP of ≥120 minutes was associated with a 81%

sensitivity and 92% specificity for short-term catheters (<30 days) and 93% sensitivity and 75% specificity for long-term catheters (>30 days). Although this diagnostic test has been implemented in routine clinical practice, some authors have reported that DTP is not useful for diagnosis of CRBSI in medical surgical intensive care units<sup>47</sup>. These differences can be attributed to the definition of CRBSI used<sup>48</sup> or to the type of microorganism causing the CRBSI<sup>49–51</sup>. A recent report suggested that a DTP of ≥120 minutes was the optimal cut-off point for diagnosis of *Candida* spp. CRBSI (85% sensitivity and 82% specificity), except for *Candida glabrata*<sup>51</sup>. However, in a study of catheter-related candidaemia (CRC) that included mainly *Candida albicans* and *Candida parapsilosis*, Bouza et al.<sup>49</sup> found that a DTP of ≥120 minutes had high sensitivity (94.7%) but low specificity (40%). In general, the accuracy of the DTP method requires accurately tracking how long it takes the blood cultures from the source (central venous catheter vs. peripheral vein) to become positive. The method also relies on the cultures being placed in the automated machine at the same time<sup>46</sup>.

For suspected CRBSI, detection of the identical microorganism in blood cultures obtained via peripheral venipuncture and the suspected catheter was recently evaluated as a means of diagnosing CRBSI without catheter removal. Although most laboratories use antimicrobial susceptibility testing and biochemical identification to establish identity without using molecular techniques, which seems to be the most practical way to compare isolates, the possibility of polyclonal infection should always be considered, as several studies have demonstrated that polyclonal infections are probably more common than previously suspected<sup>52–54</sup>.

## RECOMMENDATIONS

1. Positivity of blood cultures obtained through the catheter ≥120 minutes before those obtained from a peripheral vein with the same microorganism is highly suggestive of CRBSI. An optimal DTP cut-off for the diagnosis of catheter-related candidemia has not been established. (A-II).
2. The interpretation of DTP should consider adherence to the procedural technique used and the type of microorganism (A-II).

3. Rapid microbial identification by MALDI-TOF MS from a positive blood culture significantly reduces time to identification of microorganisms and has clinical impact on the management of patients with suspected bloodstream infection (A-II).

*How should quantitative blood cultures be taken and interpreted?*

The quantitative methodology is based on lysing red blood cells with different detergents, centrifugation (i.e., lysis-centrifugation) and inoculating the sediment into different culture media and in different atmospheres<sup>55,56</sup>. This system has shown better results than conventional methods in terms of detection times and specificity, but is relatively complex and the sample must be processed within 20-30 minutes of inoculation of the blood into the tube<sup>26,27</sup>. There are no specific guidelines for the procedure of obtaining blood cultures, so that the recommendations for conventional blood cultures above also apply to quantitative blood cultures<sup>15,16,25-27,32</sup>, except for inoculation into the bottle. In the lysis-centrifugation system, 10 ml of blood is inoculated into the lysis tube, which contains the specific amount of detergent for this volume. After inoculation, the blood and detergent should be gently mixed before centrifugation is performed. Another currently used method for diagnosing CRBSI is the pour plate method<sup>57</sup>. Briefly, for each quantitative blood culture, 1-3 ml of blood is mixed with 20 ml of previously melted brain heart infusion agar at ~56 °C in Petri plates, then the plates are incubated aerobically for 4 days at 35-37 °C.

The number of blood cultures required is similar to conventional blood cultures. For diagnosis of CRBSI, several authors have demonstrated that a differential colony count that is (5 to 10 times) greater for the intravascular catheter blood culture than the peripheral vein culture is indicative of CRBSI<sup>42,58-61</sup>. In a meta-analysis performed by Safdar et al<sup>62</sup>, the differential quantitative blood culture (DQBC) was the best approach for diagnosing CRBSI without catheter removal, with a pooled sensitivity of 0.79 (95% CI: 0.74, 0.84), and pooled specificity of 0.99 (95% CI: 0.98, 1.0). There is some controversy about the cut-off point of DQBC. A study that evaluated different cut-off points

for paired quantitative blood cultures for the diagnosis of CRBSI showed that the DQBC was not useful with short-term central venous catheters (CVCs), although in long-term CVCs, DQBCs of 2:1 or greater, or 5:1 or greater were sensitive, but associated with low specificity and positive predictive values<sup>61</sup>. Quantitative blood cultures are labor intensive and expensive, which makes them less practicable for routine use.

#### **RECOMMENDATION**

1. A quantitative blood culture with a colony count 3 times greater in a sample drawn through a catheter than from the peripheral vein supports a diagnosis of CRBSI (A-II).

*What particular aspects should be considered for the diagnosis of CRBSI in patients on hemodialysis?*

For patients without a functioning vascular access, central venous catheters (CVC) have become an acceptable means of vascular access for hemodialysis (HD), although their clinical usefulness is severely limited by potential infectious complications<sup>63–65</sup>. The relative risk of a CVC causing CRBSI in HD patients is estimated to be approximately 10 times higher than the risk of bacteremia in patients with an arteriovenous fistula or graft<sup>63,65,66</sup>.

In HD patients, particularly in the outpatient setting, it is difficult to meet the standard microbiological criteria of paired quantitative blood cultures and differential time to positivity to confirm diagnosis of CRBSI. The limitations of the standard diagnostic criteria for CRBSI include the following:

1. Obtaining peripheral blood cultures may be impossible in up to 40% of HD patients, either because their peripheral veins have been exhausted or because of the need to avoid venipuncture in veins intended for the future creation of a dialysis fistula or graft<sup>25,66–69</sup>.
2. If blood cultures are drawn during the dialysis session when systemic blood is circulating through the catheter, there is no significant difference between peripheral and catheter blood culture results, so that peripheral sampling can be omitted<sup>67–69</sup>.

3. In the absence of concurrent blood cultures from the catheter and a peripheral vein, there is a risk that a positive blood culture corresponds to a source of infection other than the catheter<sup>67,68</sup>.
4. In the outpatient setting, longer preincubation due to excessive time for transportation may lead to a false-negative DTP<sup>25,69</sup>.

## RECOMMENDATIONS

1. Whenever possible, paired blood samples from the CVC and a peripheral vein should be obtained for CRBSI diagnosis in hemodialysis patients (A-II).
2. Peripheral blood samples should be obtained from veins that are not intended for future creation of dialysis fistulae or grafts. The veins of the hand for outpatients and hand or femoral veins for hospital inpatients should be used to obtain peripheral blood cultures (A-III).
3. If a blood sample cannot be drawn from a peripheral vein, two separate samples should be drawn, 10 to 15 minutes apart, through the CVC or the dialysis circuit connected to the catheter (B-II).

### *What other conservative techniques may be used for diagnosis of CRBSI?*

Conservative methods for the diagnosis of CRBSI include endoluminal brushing, superficial cultures of the skin around the insertion site and catheter hubs, and the Gram stain with acridine orange leukocyte cytopspin (AOLC) test<sup>42,43,70-72</sup>. Endoluminal brushing, a method of sampling the internal surface of the catheter, showed high sensitivity (95% to 100%) and specificity (84% to 89%) in two studies<sup>72,73</sup>, although the procedure is impractical and unreliable and major side-effects have been reported, such as cardiac arrhythmias and embolization with subsequent bacteremia<sup>56</sup>. Superficial cultures (semiquantitative cultures of skin around the catheter insertion site and catheter hubs) have also been proposed for the diagnosis of CRBSI<sup>43</sup>, based on a sensitivity and specificity of 78% and 92%, respectively. It has been suggested that superficial and peripheral blood cultures be combined to screen for CRBSI, reserving DQBC as a more specific technique for confirmation. Other authors have also reported on the Gram stain-AOLC test as a rapid method for

diagnosis of CRBSI<sup>70</sup>. The method requires two 50 µL samples of catheter blood. After several steps, including the use of cytopspin technology, a monolayer of leukocytes and microorganisms is placed on two slides, then stained with either acridine orange or Gram stain, and viewed by ultraviolet and light microscopy, respectively. The authors reported a 96% sensitivity and 92% specificity<sup>70</sup>. In the meta-analysis by Safdar et al.<sup>62</sup>, the overall sensitivity and specificity of the AOLC test were 72% and 91%, respectively. Generally speaking, these methods have not been validated by other authors and are not widely used in clinical laboratories. Table 2 gives a brief summary of these conservative methods and those requiring catheter removal.

## RECOMMENDATIONS

1. Endoluminal brushing of the internal surface of the catheter may be useful for diagnosis of CRBSI. However, the procedure is impractical and major side-effects have been reported (C-III).
2. Semiquantitative cultures of skin around the catheter insertion site and catheter hubs with  $\geq 15$  cfu may be indicative for CRBSI. These procedures must be combined with peripheral blood culture (B-II).
3. Gram stain-acridine orange leukocyte cytopspin (AOLC) of catheter blood may be used as a rapid method for diagnosis of CRBSI. The presence of any microorganisms in a minimum of 100 high-powered fields may be indicative of CRBSI (B-II).

## *What is the value of molecular techniques for the diagnosis of CRBSI?*

Most molecular techniques for diagnosis of CRBSI without catheter withdrawal are performed directly on blood samples drawn through catheters. Various molecular methods have been applied to different patient populations. A 16S rDNA analysis of blood drawn through vascular access devices in patients with hematologic disorders had a 100% positive predictive value for CRBSI<sup>74,75</sup>. Other authors used pulsed-field gel electrophoresis (PFGE) to confirm CRBSI caused by coagulase-negative staphylococci (CoNS) in patients with neutropenia<sup>76</sup>. Most studies are based on real-time PCR, such as LightCycler® SeptiFast or Gene Xpert®, which are demonstrated to be a useful

complementary diagnostic tool for blood cultures, especially in patients receiving antibiotics.<sup>77–80</sup> There is very little data about the use of molecular techniques with samples other than blood to confirm a CRBSI episode<sup>81</sup>.

Although direct molecular detection techniques for detecting microorganisms in the blood and other samples are a promising approach for improving patient management and outcome by streamlining the diagnosis of CRBSI, they are still currently unable to replace the traditional culture and remain expensive and time-consuming<sup>82,83</sup>.

#### ***RECOMMENDATION***

1. There is not enough information to recommend implementing molecular techniques in clinical practice for CRBSI diagnosis (C-II).

#### ***Diagnosis of CRBSI with catheter withdrawal***

*When should a catheter tip be sent for culture?*

Diagnosis of CRBSI requires establishing the presence of a bloodstream infection (see section *How should blood cultures be taken?*) and demonstrating that the infection is related to the catheter. As a general recommendation, a catheter culture should only be obtained when a CRBSI is suspected<sup>84</sup>, thus avoiding unnecessary cultures. Several factors should be taken into consideration when determining whether the catheter should be removed: the type of catheter, ease of new catheter insertion, immune status, the severity of the underlying illness of the patient, and the presence and severity of sepsis<sup>85–88</sup>.

#### ***RECOMMENDATION***

1. Catheter cultures should only be obtained when CRBSI is suspected (A II).

*How should a catheter be sent to and processed in the Microbiology Laboratory?*

After pulling the catheter, its tip should be cut to a length of 5 cm approximately, under sterile conditions and avoiding contact with the patient's skin, and then placed in a dry, sterile container for transport. The catheter tip should be stored at 4-8 °C<sup>27</sup> while transport to the laboratory is arranged.

The most widely used laboratory technique is the semi-quantitative method described by Maki, in which the catheter segment is rolled across a blood agar plate using sterile forceps. After overnight incubation, the number of colony-forming units (CFU) is counted<sup>89</sup>. One limitation of this method is that it mainly detects colonization on the external surface of the catheter. This is more of a concern with long-term catheters, where luminal colonization more frequently leads to bloodstream infections<sup>56,90</sup>. In 1980, Cleri described a quantitative culture method to improve the detection of microorganisms progressing inside the catheter lumen<sup>91</sup>. Quantitative cultures of the endolumen were obtained by immersing the catheter segment in 2-10 ml of tryptic soy broth (TSB), then flushing it three times with a syringe. The broth was serially diluted 100-fold. 0.1 ml of each dilution was streaked onto sheep blood agar and the number of CFUs counted after incubation<sup>91</sup>.

Brun-Bruisson et al.<sup>92</sup> simplified Cleri's technique by placing the catheter segments into a test tube with 1 ml of sterile distilled water. After vortexing for 1 minute, 0.1 ml of the suspension is plated onto blood agar. Other modifications of quantitative endoluminal cultures include a quantitative sonication technique<sup>93</sup>, in which the catheter tip is placed in 10 ml of TSB and sonicated for 1 min. 0.1 ml of both the sonicated broth and a 1:100 dilution of the broth are plated onto blood agar and the number of colony-forming units counted.

In order to distinguish between colonization on the internal and external surfaces of the catheter, Liñares et al.<sup>90</sup> used the semiquantitative method for culturing the catheters<sup>89</sup>, then a modified quantitative technique, flushing each catheter lumen with 2 ml of TSB, which was then serially diluted and plated.

All quantitative methods are time-consuming, whereas the simplicity of semiquantitative techniques has contributed to their widespread use in clinical microbiology laboratories<sup>43,94</sup>. Several prospective studies have compared Maki's semiquantitative technique with quantitative methods (sonication and vortexing) for detection of CRBSI and concluded that the three methods exhibited similar reliability, although Maki's semiquantitative technique was simpler to use<sup>95,96</sup>.

The predictive values of quantitative or semiquantitative methods may vary depending on the type and location of the catheter, the culture methodology used, and the source of catheter colonization.<sup>97</sup> For example, skin-colonizing microorganisms are more likely to colonize the external surface of a recently inserted catheter, so that Maki's semiquantitative method would be very sensitive for identifying this colonization. By contrast, a catheter that has been in place for more than a week could become colonized intraluminally via the hub, rendering the roll plate method less sensitive. In this case, methods that obtain samples for culture from both internal and external surfaces are more sensitive<sup>95</sup>.

## RECOMMENDATIONS

1. The most reliable diagnostic methodologies for catheters sent to culture are the semiquantitative (roll plate) or quantitative (vortex or sonication methods) (A-II).
2. Qualitative cultures (culture of the catheter tip by broth immersion) are unreliable for distinguishing between contamination and infection, and are not therefore suitable for the diagnosis of CRBSI (A-II).

### *How should the results of catheter cultures be interpreted?*

A semiquantitative catheter cultures discriminate between catheters as the cause of infection and non-significant colonization. The catheter is considered to be the source of infection if growth from a culture of the catheter tip is  $\geq 15$  CFU, whereas  $< 15$  CFU with no associated clinical signs is considered to be catheter colonization<sup>89</sup>. The cut-off point of  $\geq 15$  CFU is significantly associated with clinical signs and bacteremia, with a 76% specificity<sup>89</sup>. Subsequent studies have validated the semiquantitative culture technique for evaluating catheter-related infections<sup>98,99</sup>. There is no established cut-off point for mycobacteria and fungi.

For quantitative catheter cultures (flushing the internal surface and vortexing), the cut-off point has been established at  $10^3$  CFU/segment, based again on its association with bacteremia in CRBSI. Colony counts of less than  $10^3$  CFU are considered intermediate, possible contamination, or the early stages of colonization<sup>91,92</sup>. For quantitative cultures based on sonication, a cut-off point of

$>10^2$  CFU was established to discriminate between catheter infection and catheter colonization<sup>93</sup>. In general, semiquantitative and quantitative cultures give comparable results, although the semiquantitative procedure is easier and faster in practice<sup>27,100</sup>.

## RECOMMENDATIONS

1. The presence of more than 14 CFU per plate by semiquantitative culture (roll-plate) is indicative of significant catheter colonization (A-II).
2. A count of  $10^3$  CFU/segment or more using quantitative culture methods based on vortexing or flushing the internal surface reflects significant catheter colonization (A-II).
3. Counts above  $10^2$  CFU/segment for quantitative culture methods based on sonication indicate significant catheter colonization (A-II).

### *How should a subcutaneous reservoir be processed?*

Venous access devices (VADs) are widely used for long-term access to the vascular system, mainly in cancer patients. The diagnosis and management of CRBSI also includes a recommendation to perform a qualitative culture of the port reservoir contents as well as a semiquantitative culture of the catheter tip if VAD-related bloodstream infection (VAD-RBSI) is suspected. This has been thoroughly studied in patients with suspected VAD-RBSI by comparing VAD cultures with blood cultures obtained before removal. In all studies, the catheter tip cultures failed to detect several VAD-RBSI episodes, whereas cultures of the endoluminal content (thrombotic material) had better predictive value<sup>101–104</sup>.

Bouza et al. assessed the validity values of cultures obtained from multiple sites of 223 VADs that had been withdrawn for some reason and confirmed that the rate of VAD colonization improved when they not only obtained cultures from the catheter tip and the inside of the port, but also from the sonication fluid used to obtain microorganisms from the external surface of the port<sup>105</sup>. In addition, del Pozo et al. assessed the yield from the septum of 240 VAPs after sonication. The latter procedure showed the highest sensitivity and specificity (78% and 93%, respectively) for diagnosing VAD colonization with a cut-off of 110 CFU/ml<sup>106</sup>.

These recent findings will probably have an impact on the routine laboratory processing of pulled VADs, since confirmation of VAD-RBSI requires performing cultures of the catheter tip, and the inner and outer surfaces of the port. There is no consensus statement for thresholds for VAD cultures.

#### ***RECOMMENDATION***

1. Venous access devices removed for suspected CRBSI should be sent to the microbiology laboratory. Routine processing should include a combination of cultures from different parts of the VAD, including a culture after septum sonication and semiquantitative catheter tip cultures (B-II).

*What is the present value of molecular techniques for the diagnosis of CRBSI after catheter removal?*

Diagnosis of CRBSI requires confirmation that the microorganisms isolated from blood and catheter tip cultures are phenotypically identical. A recent study using quantitative PCR for the detection of CoNS suggested that the role of the catheter as a source of bacteremia may be overestimated<sup>107</sup>. Indeed, the conventional microbiological procedures used to diagnose CoNS CRBSI performed badly when compared with an evaluation by PFGE of different morphotypes of CoNS isolated from catheter tip and blood cultures<sup>108</sup>. By contrast, using microsatellite markers, the genotypes of *Candida* isolates recovered from blood cultures and catheter tips were a match in 91% of patients studied<sup>109</sup>.

Due to its low sensitivity, 16S rRNA polymerase chain reaction (PCR) has not managed to replace the conventional culture and there are at present no data about the application of molecular methods to non-tunneled catheters. On the other hand, the application of 16S rRNA PCR using endoluminal samples increased detection of venous access device-related bloodstream infection (VAD-RBSI) in patients undergoing antibiotic therapy by 21.1%<sup>110</sup>.

In summary, molecular methods have the potential to improve diagnosis of CRBSI in patients undergoing antibiotic therapy, although these techniques have not been standardized.

## RECOMMENDATION

1. 16S rRNA PCR could be performed with septum sonication fluid to rule out or confirm VAD-RBSI in patients undergoing antibiotic therapy (C-III).

## Diagnosis of local signs of infection

*What samples should be taken and how should they be interpreted when an insertion site infection is suspected?*

Insertion site infections are characterized by signs of inflammation, including induration, erythema, warmth, and pain or tenderness within 2 cm of the catheter insertion site. They may also be associated with other signs and symptoms of infection, such as fever or purulent discharge from the insertion site, with or without a concomitant bloodstream infection<sup>6,111</sup>. A microbiologically documented insertion site infection is defined as exudate with a positive culture at the catheter insertion site<sup>6,111</sup>. The sensitivity and positive predictive value of local inflammation for the diagnosis of CRBSI is shown to be very low<sup>112</sup>. When catheter infection is suspected and there is exudate at the catheter insertion site, the exudate should be sent for Gram staining, routine culture, and additional culture for fungi as indicated when assessing immunocompromised patients<sup>25</sup>. Blood cultures should also be drawn<sup>6,111,112</sup>.

In the absence of local signs of infection, the results of several studies suggest that semi-quantitative cultures of swabs of skin taken from around the insertion site and surface cultures from the internal surface of the catheter hubs may be useful for ruling out catheter colonization and infection, and so avoiding unnecessary catheter withdrawals<sup>43,81,113–115</sup>. For skin samples, a dry cotton swab should be rubbed over a 2 cm<sup>2</sup> area around the insertion site. For hub samples a small alginate swab should be introduced into each hub and rubbed repeatedly against its inner surface<sup>43,113</sup>. Semi-quantitative growth of <15 CFU from both the insertion site and the catheter hub enables CRBSI to be ruled out<sup>43,113</sup>, although surface cultures show very low specificity and positive predictive value. Combining a semiquantitative culture of the subcutaneous tract with a hub swab culture improves specificity and positive predictive values<sup>116</sup>.

VAD-related infection should be suspected if a patient exhibits signs of a local infection, such as pain or erythema at the implant site<sup>104</sup>. A local complicated infection is defined as infection of the tunnel or pocket, with extended erythema or induration (more than 2 cm), purulent collection, skin necrosis and spontaneous rupture and drainage. Clinical signs of local infection, such as redness or purulent exudate, have high specificity but low sensitivity<sup>101,104</sup>. A recent study showed that 23% of patients with VAD-related infection had local signs of infection<sup>117</sup>. In such cases, a culture of purulent fluid and/or necrotic tissue surrounding the port is required. Blood culture from peripheral veins should also be performed in order to rule out CRBSI.

## **RECOMMENDATIONS**

1. When there is exudate at the catheter insertion site, it should be sent for Gram staining and culture. Blood cultures should also be drawn (A-III).
2. In patients with suspected catheter-related infection but negative superficial cultures (growth of <15 CFU from both the insertion site and catheter hub cultures), the possibility of infection can reasonably be ruled out (B-II).

## **Catheter related bloodstream infection treatment**

The main antimicrobial drug and dosage regimens that should be used for CRBSI are shown in Table 3.

### *When can a catheter be retained until blood cultures are available?*

Two studies found no differences in outcome when early CVC removal was compared with a watchful waiting strategy for suspected CRBSI in patients with non-tunneled catheters<sup>118-120</sup>. These studies excluded patients with neutropenia, solid organ or hematologic malignancy, immunosuppressive drugs or radiation therapy, organ transplants, intravascular foreign bodies, hemodynamic instability, suppuration or frank erythema/induration at the insertion site, as well as bacteremia or fungemia. One of these ICU studies was a randomized single-center clinical trial<sup>118</sup> and the other was prospective,

observational, and multicenter<sup>119</sup>. In the multicenter study, CRBSI was confirmed in only 12% of patients and there was no difference in mortality between immediate and late removal of the CVC. Another randomized trial demonstrated that, with critically ill patients, the DTP method makes it possible to use a watchful waiting strategy up to definitive diagnosis of CRBSI<sup>121</sup>. It should be noted that catheter exchange is not without its risks, and severe complications, although fortunately uncommon, can occur<sup>122</sup>.

#### **RECOMMENDATION**

1. Immediate removal of the CVC is not routinely recommended when CRBSI is suspected in patients who are hemodynamically stable, without immunosuppressive therapy, intravascular foreign bodies or organ transplantation, no suppuration at the insertion site or bacteremia/fungemia, (A-I).

#### *When is it safe to perform a catheter exchange over a guidewire?*

A CVC replacement can be inserted by percutaneous venipuncture at a new site or by using the Seldinger over-the-guidewire technique. A meta-analysis of 12 randomized controlled trials (RCT)<sup>123</sup> that evaluated guidewire exchange versus new-site insertion found non-significant differences between the two for the prevention of CRBSI. Guidewire exchange was associated with fewer mechanical complications (8 RCTs, relative risk = 0.48, 95% confidence interval = 0.12 to 1.91) but also a higher rate of catheter colonization (9 RCTs, relative risk = 1.26, 95% confidence interval = 0.87 to 1.84), catheter exit-site infections (5 RCTs, relative risk = 1.52, 95% confidence interval = 0.34 to 6.73) and catheter-related bacteremia (9 RCTs, relative risk = 1.72, 95% confidence interval = 0.89 to 3.33)<sup>123</sup>. A study of 1,598 CVCs in critically ill patients showed that over-the-guidewire exchange was associated with the development of CRBSI<sup>124</sup>. On the other hand, inserting tunneled hemodialysis catheters using elective guidewire exchange from non-tunneled catheters was not associated with a higher incidence of catheter infections, and venous access was preserved in these high-risk patients<sup>125</sup>.

Guidewire exchange is not indicated for patients with documented catheter infections or CRBSI<sup>126</sup>. Using guidewire-assisted exchange to replace a malfunctioning catheter is an option if there is no evidence of infection at the catheter site and new percutaneous venipuncture is not recommended because of a high risk of complications (difficult venous access, bleeding diathesis).

## RECOMMENDATIONS

1. Routine replacement of a CVC by guidewire exchange is not recommended because this strategy is associated with a higher risk of associated infectious complications. (B-II)
2. Guidewire exchange of a CVC is contraindicated in patients with documented catheter related infections. (A-II)
3. Guidewire exchange should be restricted to patients with very difficult venous access (i.e., extensive burns, morbid obesity, or severe coagulopathy) and without documented catheter infection (B-II). In this case, a meticulous aseptic technique and a culture of the catheter tip are mandatory. (A-III)
4. If the catheter tip culture is positive, the new line, inserted over a guidewire, should be re-placed via a new direct venipuncture. (C-III)

*What should be done if the catheter tip culture is positive, but the blood cultures are negative?*

There is very limited data about the clinical implications of a positive CVC tip culture with negative blood cultures taken at the time of catheter removal.

Two retrospective studies<sup>127,128</sup> concluded that an intravascular catheter colonized with *S. aureus* is a risk factor for subsequent *S. aureus* CRBSI. Antibiotic therapy initiated within 24 hours of catheter removal significantly reduced the risk for subsequent *S. aureus* bacteraemia (SAB).

Another retrospective multicenter study showed a lower incidence of septic complications after the removal of a colonized catheter in patients with early antibiotic treatment (13% vs. 4%) (OR = 4.2; 95% CI = 1.1-15.6). In that study, exit-site infection was also a risk factor for the development of *S. aureus* CRBSI (OR = 3.39; 95% CI = 1.19-9.34).<sup>127</sup> A meta-analysis of four

retrospective studies yielded a pooled OR of 5.8 (95% CI = 2.6-13.2) for SAB when antibiotic therapy was not initiated. The number needed to treat to prevent 1 episode of SAB was 7.4<sup>129</sup>. Conversely, a more recent retrospective study concluded that administration of early antistaphylococcal therapy had no impact on outcome, which was defined as *S. aureus* infection within 3 months of catheter withdrawal or death with no obvious cause. The only factor independently associated with a poor outcome were clinical signs of sepsis at the time the catheter was removed (OR = 20.8; 95% CI = 2.0-206.1)<sup>130,131</sup>.

A retrospective study of patients with CVC tips colonized with *Candida* spp. observed that the incidence of subsequent candidemia (SC) was only 1.7% and a multivariate analysis of risk factors for poor prognosis showed that antifungal therapy was not protective in this setting (OR = 0.82; 95% CI = 0.27-2.47)<sup>132</sup>. A more recent study showed that the incidence of SC was 2.5% and that administration of antifungals was not protective in 55% of patients<sup>133</sup>. Another study however showed that the risk of infectious complications following catheter removal was higher when *Candida* spp. were involved (7.7%) than in the case of bacterial infection (1.8%) and initiating antifungal therapy was suggested for all patients with positive catheter tip cultures and negative blood cultures<sup>134</sup>.

No clear recommendations can be given if the catheter is colonized with other microorganisms. The decision should be individualized, although antimicrobial therapy would be justified only in patients with septic shock and no other obvious explanation for the clinical picture.

## RECOMMENDATIONS

1. Antibiotic treatment (i.e., 5-7 days) should be given to patients with catheter tip cultures positive for *S. aureus* and negative blood cultures if the patient shows systemic or local infection (B- II).
2. In non-neutropenic patients or those without valvular heart disease, the presence of a catheter tip culture positive for *Candida* spp. and negative or unavailable blood cultures should be assessed on an individual basis before starting systematic antifungal treatment. Antifungal treatment should not be prescribed for patients without systemic signs of infection (B-II).

3. No clear recommendations can be given for catheters colonized with other microorganisms (C-III).

## **Empirical antimicrobial therapy**

### *What is the empirical antimicrobial therapy for CRBSI?*

The initial choice of antimicrobial should be based on an assessment of the risk factors for infection, the severity of the clinical picture and the likely pathogens associated with the specific intravascular device. Figure 1 summarizes the recommended empirical approach for a patient with a high index of suspicion for CRBSI.

Patients with *S. aureus* CRBSI are at high risk for hematogenous metastasis, especially when the catheter cannot be removed and/or antibiotic treatment is not appropriate<sup>135</sup>. As most CoNS are methicillin-resistant, the choice of empirical therapy should include antibiotics with activity against these strains. Vancomycin is the most commonly prescribed antimicrobial for CoNS and methicillin-resistant *S. aureus* (MRSA) bacteremia in recent decades. Studies comparing the efficacy and safety of glycopeptides (i.e., vancomycin vs. teicoplanin) for *Staphylococcus* spp. (including MRSA) bacteremia have not observed significant differences<sup>136,137</sup>, although clinical isolates of *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* have been reported with reduced susceptibility to teicoplanin<sup>138</sup>.

Vancomycin is associated with lower clinical success rates for MRSA bacteremia with MICs  $\geq 1.5$  mg/l (measured by E-test)<sup>139,140</sup>. In a case-control study focusing on cases of MRSA bloodstream infection with a vancomycin MIC  $\geq 1.5$  mg/l (measured by E-test), a higher survival rate was observed in the patient group treated with daptomycin<sup>141</sup>. Multivariate analysis confirmed that renal impairment and previous therapy with vancomycin were associated with significantly higher clinical failure. The impact on the outcome of bacteremia caused by CoNS with vancomycin MIC  $\geq 1.5$  mg/l (measured by E-test) is an unresolved issue.

Previous studies have indicated that vancomycin is inferior to beta-lactams (i.e., cefazolin or oxacillin) for the treatment of methicillin-susceptible *Staphylococcus aureus* (MSSA) bloodstream infections<sup>142-144</sup>. This would justify

the inclusion of a beta-lactam in the empirical treatment of any suspected case of CRBSI. A recent study compared beta-lactams and vancomycin for empirical and definitive therapy of MSSA bloodstream infections among 5,787 patients from 122 hospitals<sup>145</sup>. Patients who received definitive therapy with a beta-lactam had a 35% lower mortality compared with patients who received vancomycin (HR = 0.65; 95% CI = 0.52–0.80) after controlling for other factors<sup>145</sup>.

Daptomycin is a lipopeptide antibiotic with *in vitro* activity against Gram-positive bacteria and is also more bactericidal than vancomycin<sup>146,147</sup>. The only randomized trial that has compared daptomycin with vancomycin or a β-lactam concluded that daptomycin was noninferior to vancomycin<sup>148</sup>. In a recent cohort study including 579 episodes of bacteremia caused by MRSA, no significant differences were observed in the mortality of patients treated with vancomycin or daptomycin (OR = 1.42 [95% CI = 0.83-2.44])<sup>149</sup>. However, a recent study analyzing the efficacy of daptomycin in 40 cancer patients treated for Gram-positive CRBSI (including *S. aureus*) compared with a historical control group of 40 patients treated with vancomycin confirmed faster bacteriological eradication and clinical resolution in the daptomycin group<sup>150</sup>.

In a randomized clinical trial of skin-structure infection and CRBSI with *S. aureus*, including MRSA, linezolid and its comparators showed similar efficacy for CRBSI<sup>151</sup>. A meta-analysis of 5 randomized controlled trials of MRSA bacteremia observed that linezolid was noninferior to vancomycin<sup>152</sup>.

## RECOMMENDATIONS

1. If CRBSI is suspected, antimicrobial therapy should be started as soon as possible with a bactericidal agent active against *S. aureus* and CoNS, especially if associated with sepsis or septic shock (B-II).
2. Vancomycin is recommended for empirical therapy in patients with suspected CRBSI (B-II). Teicoplanin is not recommended as empirical therapy, given the existence of coagulase-negative staphylococci with reduced susceptibility to teicoplanin (C-III).
3. Daptomycin can be administered for cases of CRBSI with septic shock (C-III), acute kidney injury (B-III), to patients with recent exposure to vancomycin (>1 week in the past 3 months) (C-III) or if the local

prevalence of *S. aureus* isolates with vancomycin MIC  $\geq 1.5$   $\mu\text{g}/\text{ml}$  is high (C-III). The local prevalence of *S. aureus* isolates with vancomycin MIC  $\geq 1.5$   $\mu\text{g}/\text{ml}$  supporting routine empirical use of daptomycin remains undefined.

4. Linezolid should only be used in patients with contraindications for the previous agents (B-II).

*When should empirical coverage of Gram-negative bacilli or fungi be added?*

The incidence of Gram-negative bacilli (GN)-CRBSI is reported to be 17% to 25% of all episodes of CRBSI<sup>153,154</sup>. GN-CRBSI is particularly relevant during outbreaks and in patients with special conditions, such as spinal cord injuries, femoral catheters, neutropenia and hematologic malignancy, gastrointestinal colonization, prolonged ICU stay, post-operative status or diabetes<sup>155-157</sup>. In some centers, the predominance of GN-CRBSI has been related to an increase in transplants (solid organ or hematologic bone marrow)<sup>157</sup> and the implementation of bundled strategies for the prevention of CRBSI including the use of chlorhexidine/silver sulphadiazine-impregnated catheters, which preferentially prevent Gram-positive CRBSI<sup>158</sup>. In a recent report, solid organ transplant, prior use of penicillin and hospital stays of more than 11 days were independently associated with a significantly higher risk of GN-CRBSI, whereas, cirrhosis, diabetes and use of quinolones were associated with a higher risk of Gram-positive CRBSI<sup>154</sup>. Femoral catheterization is associated with a higher incidence of CRBSI due to Gram-negative bacilli than at other anatomic sites, so that empirical antibiotic coverage for Gram-negative bacilli has been suggested when CRBSI is suspected in patients with femoral access<sup>159</sup>. No clinical trial has validated the benefits of specific drugs for the management of GN-CRBSI; empirical coverage should be based on local antimicrobial susceptibility data and disease severity<sup>158</sup>.

A prospective study of risk factors for yeast bacteremia found that the rate of *Candida* spp. CRBSI was significantly higher in femoral catheters than at other catheter sites (16.67% vs. 1.92%;  $p = 0.035$ )<sup>159</sup>. A recent study, however, identified only solid tumors (OR = 3.11; 95% CI = 1.75-5.53), total parenteral nutrition (OR = 2.65; 95% CI = 1.39-5.06) and administration of anti-anaerobic

agents (OR = 2.22; 95% CI = 1.03-4.79) as independent variables for *Candida* CRBSI. In that study, the (1,3)- $\beta$ -D-glucan (BDG) test was positive in 94.6% (35/37) of *Candida* spp.-CRBSI patients and 9.4% (10/106) of non-candidal CRBSI cases<sup>160</sup>. For ICU patients, multivariate logistic regression analysis identified severity of illness on the day of candidemia (as measured by the SOFA score) as the only potential risk factor for CRBSI caused by *Candida* spp.<sup>161</sup>.

## RECOMMENDATIONS

1. Patients with suspected CRBSI should receive empirical antibiotic therapy (in addition to coverage for Gram-positive pathogens) to cover Gram-negative bacilli under any of the following circumstances: hemodynamic instability (septic shock), neutropenia or hematologic malignancy, solid organ or bone marrow transplant, femoral catheter in place, a high index of colonization with Gram-negative bacilli or prolonged ICU admission (C-III).
2. Antimicrobial therapy should be adapted to local epidemiology and must include an antipseudomonal agent (i.e., piperacillin-tazobactam, carbapenems, a fourth-generation cephalosporin, aztreonam, quinolones or aminoglycosides) (A-II). Aztreonam and cephalosporins should be avoided in patients with colonization or at risk for extended-spectrum  $\beta$ -lactamase infections (A-I).
3. The need for empirical antifungal therapy in a patient with suspected catheter-related candidemia should be evaluated along with the possibility of catheter removal (A-III).
4. Empirical therapy for suspected catheter-related candidemia should be considered in patients who are hemodynamically unstable with one or more of the following conditions: total parenteral nutrition, prolonged use of broad-spectrum antibiotics, malignancy, femoral catheterization, colonization due to *Candida* spp. at multiple sites or intense previous anti-anaerobic therapy (C-III).
5. The use of biomarkers (such as 1,3- $\beta$ -D-glucan) may be useful when considering initiation of empirical antifungal treatment (B-III).

*What particular aspects should be considered in the empirical treatment of CRBSI in patients on hemodialysis?*

Vascular catheters are the leading source of bacteremia in HD patients<sup>162,163</sup>. Bacteremia usually develops when the catheter is in use. Catheter salvage should be a priority in these patients.

Conservative management is associated with a higher success rate when a combination of systemic antibiotics and catheter antibiotic lock protocol is used<sup>164–167</sup>.

The microorganisms that cause CRBSI in hemodialysis patients are similar to those observed in other patient populations, although usually with a higher proportion of *S. aureus* in most series<sup>168–171</sup>. *S. aureus* CRBSI is one of the most difficult microorganisms to treat while maintaining a catheter in place due to its propensity to cause septic complications, treatment failure and relapses<sup>172,173</sup>. *S. epidermidis* CRBSI, however, has shown excellent results when treated conservatively by combining systemic and local antibiotics during the interdialytic period<sup>166</sup>.

Alternatively, if retaining the catheter is not possible, catheter exchange over a guidewire has been shown to be safe. This approach could lead to higher cure rates for *S. aureus* infections than treatment based on antibiotic lock therapy<sup>166</sup>. Systemic antibiotics should be administered taking into consideration the PK/PD characteristics of each particular drug for patients with end-stage renal disease or undergoing hemodialysis.

## **RECOMMENDATIONS**

1. Conservative management of CRBSI should be attempted with hemodialysis patients. Combining systemic and local intracatheter antibiotics is associated with better results when compared to systemic antibiotics alone (A-I).
2. In patients with a tunneled hemodialysis catheter, guidewire exchange is an alternative, especially when catheter removal is not feasible (C-III).

## **Targeted antimicrobial therapy**

Figure 2 summarizes the pathogen-directed management of confirmed CRBSI.

*What is the recommended directed therapy and optimal duration of treatment for CRBSI due to *Staphylococcus aureus*?*

*Methicillin-susceptible *S. aureus* (MSSA) CRBSI.* The treatment of choice is high-dose intravenous isoxazolyl penicillin, (i.e., cloxacillin). Cefazolin is an adequate alternative<sup>174–176</sup>. Treatment with other beta-lactams, including second- and third-generation cephalosporins, has been associated with increased mortality<sup>176</sup>. Likewise, the *in vitro* activity and clinical results of vancomycin therapy for MSSA have been repeatedly shown to be significantly worse<sup>142–144,177</sup>. In patients allergic to beta-lactams, the use of intravenous daptomycin yields comparable results to cloxacillin<sup>148</sup>. Infections caused by methicillin-susceptible *S. aureus* (MSSA) strains with reduced susceptibility to vancomycin (MIC  $\geq$  1.5 mg/l, measured by E-test) have been associated with worse outcomes, even when treated with cloxacillin<sup>178</sup>.

Duration of uncomplicated MSSA CRBSI treatment is 14 days, including for patients with intravenous prosthetic devices and negative transesophageal echocardiographic (TEE) findings<sup>179</sup>. Blood cultures should be obtained after 72 hours of antibiotic therapy<sup>180</sup>. The management of patients with persistent positive blood cultures and/or no clinical improvement after catheter removal is outlined elsewhere<sup>179</sup>. Duration of treatment for these episodes of complicated CRBSI is 4 to 6 weeks.

*Methicillin-resistant *S. aureus* (MRSA) CRBSI.* Vancomycin is the treatment of choice for MRSA-CRBSI<sup>179</sup>. The vancomycin dose should be adjusted to maintain trough levels of 15-20 mg/l in order to achieve the best predictor of efficacy for this antibiotic in MRSA bacteraemia (i.e., AUC/MIC  $>400$ )<sup>181</sup>. Teicoplanin is a suitable alternative to vancomycin, probably associated with fewer side effects, although serum level concentrations cannot be measured in clinical practice and the optimal dose is not well defined<sup>182</sup>. If the vancomycin MIC is  $\geq 1.5$  mg/l<sup>183,184</sup>, alternative antibiotics such as daptomycin should be considered, although there are no randomized studies available. Combination therapies for complicated MRSA bacteraemia have been reported, such as

daptomycin with a beta-lactam (i.e., cloxacillin), daptomycin with fosfomycin, and imipenem with fosfomycin. For further information, this panel recommends a guideline recently released by the SEIMC<sup>179</sup>. Duration of treatment for uncomplicated and complicated MRSA CRBSI is the same as for MSSA.

## ***RECOMMENDATIONS***

1. The treatment of choice for an episode of MSSA CRBSI is cloxacillin or cefazoline (B-I).
2. Patients allergic to beta-lactams should be treated with daptomycin (A-I) or a glycopeptide (B-II).
3. The best antimicrobial treatment for episodes caused by MSSA strains with reduced susceptibility to vancomycin (MIC  $\geq 1.5$  mg/l measured by E-test) has not been elucidated. This panel suggests using a combination of cloxacillin and daptomycin when blood cultures remain positive and/or there is no obvious clinical improvement after catheter removal (C-III).
4. Vancomycin is the treatment of choice for CRBSI caused by MRSA (B-II). Teicoplanin may be a valid alternative, especially in cases of serious side effects associated with the use of vancomycin. (C-III)
5. Alternatively, patients may be treated with daptomycin, specifically if the MIC measured by E-test is  $\geq 1.5$  mg/l (A-I).
6. Linezolid should only be used in patients when the previous agents are contraindicated (C-III).
7. For both MSSA and MRSA CRBSI, blood cultures should be obtained after 72 hours of antibiotic therapy (C-III).

*What is the recommended directed therapy and optimal duration of treatment for CRBSI due to coagulase-negative Staphylococcus (CoNS)?*

CoNS-CRBSI is associated with a significant increase in duration of hospital stay, although without attributable mortality<sup>185–187</sup>. As these infections may resolve simply by removing the catheter, some authors suggest that antibiotic therapy is not necessary in immunocompetent patients with no signs of infection and no foreign bodies. If the catheter is removed, uncomplicated CRBSI can be

treated with a short course of 5 to 7 days of antibiotics. In the infrequent case of a strain that is susceptible to methicillin, the recommended antibiotics are a penicillinase-resistant penicillin (i.e., cloxacillin 2 g/4 hours) or cefazolin. Vancomycin is the treatment of choice for MR-CoNS CRBSI. Teicoplanin is also a suitable alternative for directed therapy<sup>188</sup>.

10–14 days of antibiotic therapy is recommended for patients with intravascular devices, biomedical devices, or persistent markers of inflammation after catheter removal, although this issue has not been addressed in clinical studies. If for some reason the catheter needs to be retained, antibiotic lock therapy is a further reasonable alternative<sup>189</sup>.

*Staphylococcus lugdunensis* can cause severe infection, with an aggressive clinical course similar to *Staphylococcus aureus* infection. For this reason, *S. lugdunensis* CRBSI should be managed as for *S. aureus* bloodstream infection<sup>190</sup>.

## RECOMMENDATIONS

1. Cloxacillin or cefazolin are the treatments of choice for episodes of CRBSI caused by CoNS susceptible to methicillin (B-I).
2. For CoNS resistant to methicillin, a glycopeptide is the treatment of choice for directed therapy (B-II). Teicoplanin is recommended in the case of serious side effects associated with vancomycin. (C-III).
3. The optimal trough concentration of vancomycin for the treatment of CoNS CRBSI is an unresolved issue and this panel cannot issue a specific recommendation (C-III).
4. *S. lugdunensis* CRBSI should be managed as for *S. aureus* CRBSI (C-III).

*What is the recommended directed therapy and its optimal duration for CRBSI due to Enterococcus spp.?*

*Enterococcus* spp. are becoming an increasingly common cause of CRBSI and represent the fourth leading cause of these infections<sup>191</sup>. For susceptible isolates, ampicillin is the drug of choice. After adjusting for confounders, glycopeptide use is associated with increased mortality in patients with

*Enterococcus faecalis* bacteremia, compared with  $\beta$ -lactam therapy<sup>192</sup>. There is no information to support the superiority of combination therapy (a beta-lactam plus an aminoglycoside) over  $\beta$ -lactam monotherapy for uncomplicated CRBSI<sup>189</sup>. For other species of *Enterococcus*, particularly *E. faecium*, with a high rate of resistance to ampicillin, vancomycin is the drug of choice. For *Enterococcus faecium* isolates resistant to vancomycin, linezolid seems to be superior to daptomycin<sup>193,194</sup>. Duration of treatment is an unresolved issue, but is within the range of 7 to 14 days.

It is worth mentioning that a recent retrospective cohort study of adults with enterococcal CRBSI showed a lower in-hospital mortality rate for patients whose CVCs had been removed (18.3% vs. 37.9%;  $p = 0.03$ ). In the multivariate analysis, catheter retention was an independent predictor of mortality (OR = 3.34 [95% CI = 1.21 to 9.26])<sup>195</sup>.

#### RECOMMENDATIONS

1. Enterococcal CRBSI should be treated with catheter withdrawal and one active antimicrobial (A-III).
2. Ampicillin is the drug of choice for susceptible isolates (A-II). Vancomycin should be reserved for isolates resistant to ampicillin or cases of beta-lactam allergy. For vancomycin-resistant isolates or severe adverse effects, linezolid is preferred to daptomycin (B-III).
3. There is no evidence that combination therapy is necessary if IE has been properly ruled out (A-III).
4. Despite data suggesting that duration of treatment may be shorter, the standard 7-14 days regimen continues to be recommended (A-III).

*What is the recommended directed therapy and its optimal duration for CRBSI due to Gram-negative bacilli?*

As stated in the section on empirical therapy, no clinical trials have assessed specific antibiotic drugs in the management of GN-CRBSI. For targeted therapy, the choice should be based on susceptibility results and directed at the narrowest spectrum antibiotic. In this clinical scenario, the principles of antimicrobial stewardship should be applied wisely<sup>196</sup>. There are no studies

evaluating the length of antimicrobial therapy for patients with GN-CRBSI. Duration of therapy should be individualized, taking into account clinical factors such as resolution of symptoms or immunological status. Recommended length of treatment is usually no less than 7 days.

#### **RECOMMENDATIONS**

1. Directed therapy for GN-CRBSI should be chosen on the basis of the susceptibility results (C-III).
2. The appropriate length of antimicrobial therapy has not been elucidated, although it is recommended to continue therapy for at least 7 days (C-II).

*What is the recommended directed therapy and its optimal duration for CRBSI due to *Candida* spp.?*

Echinocandins are currently recommended for empirical therapy in candidemic patients with severe infections<sup>197,198</sup>. The decision of whether to continue with an echinocandin or use a step-down therapy to an agent with a narrower spectrum (i.e., fluconazole) is based on several factors: a) catheter removal; b) the strain is fluconazole-susceptible; c) the patient has a good clinical response and is hemodynamically stable; d) blood cultures have become negative. An open-label, non-comparative study documented de-escalation from anidulafungin to fluconazole as a safe strategy for patients with candidemia<sup>199</sup>. In critically ill patients with invasive candidiasis, an observational study confirmed that de-escalation within 5 days is not related to increased day-28 mortality<sup>200</sup>. No study has specifically assessed the impact of de-escalation of antifungal treatments in CRBSI caused by *Candida* spp. Combination therapy is not recommended for *Candida*-CRBSI<sup>197,198</sup>. Removal of an intravenous catheter is an independent determinant of survival in patients with candidemia, especially when the catheter is the source of *Candida* bloodstream infection or associated with septic shock<sup>120,201–203</sup>.

Biofilm formation is an important factor in the pathogenesis of CRBSI and the choice of the most appropriate treatment should be guided by differences in the activity of antifungals against *Candida* biofilms. Liposomal amphotericin B and echinocandins are active against *Candida* cells in biofilm, while the activity

of amphotericin B deoxycholate and azoles is poor<sup>204</sup>. In the possible situation with certain types of patient that the catheter cannot be removed for some reason and must remain in place, it is wise to use an antifungal agent with high activity against the biofilm<sup>205–208</sup>.

Based on the study protocol of relevant clinical trials, the recommended duration of treatment is two weeks (14 days) after the first negative blood culture, so that follow-up blood cultures every other day until blood cultures become negative are helpful to establish the appropriate duration of antifungal therapy.

#### RECOMMENDATIONS

1. In patients with *Candida* spp. CRBSI, this panel advocates de-escalation from an echinocandin or a lipid formulation of amphotericin B to fluconazole for susceptible isolates in clinically stable patients who have undergone catheter removal (B-II).
2. The recommended duration of therapy for candidemia without obvious metastatic complications is two weeks after the first set of negative blood cultures (B-III).
3. In candidemia, all intravascular catheters should be removed if at all feasible (B-II), particularly in patients with septic shock and when *Candida* CRBSI is suspected (B-III).
4. If a catheter that is the source of a *Candida* bloodstream infection cannot be removed for any reason and remains in place, an antifungal agent with high activity against biofilms should be used (i.e., an echinocandin or liposomal amphotericin B) (A-II).

*What is the recommended directed therapy and its optimal duration for CRBSI due to nontuberculous mycobacteria (NTM)?*

CRBSI and/or sepsis are the most common healthcare-associated types of infection due to pathogenic rapidly growing mycobacteria (RGM) in both immunosuppressed and immunocompetent patients. The organisms may not only cause mycobacteremia, but can also present as local wound exudate from an exit site or tunnel infection. The most commonly recovered RGM species or

groups include *M. fortuitum*, *M. abscessus*, and the *M. mucogenicum* group<sup>209–211</sup>. Both short- and long-term catheters should be removed in CRBSI due to mycobacteria.

The duration of treatment for NTM CRBSI varies, but is usually at least 6 to 12 weeks to prevent relapse<sup>212,213</sup>. In leukemic children, recent studies suggest that systemic infections due to mycobacteria may require up to 2 years of therapy, even if the catheter is removed. The prognosis is excellent if the catheter is pulled in addition to systemic antibiotic therapy over an extended period.

#### **RECOMMENDATIONS**

1. The treatment for CRBSI caused by NTM involves removal of the infected catheter (B-II) followed by combination antimicrobial treatment appropriate for the species involved (B-III).
2. The duration of treatment for NTM CRBSI should be 6 to 12 weeks to prevent recurrence of infection and the development of septic metastases (B-III).

*Should antimicrobials for CRBSI be administered intravenously for the entire course of treatment?*

The efficacy of treatment for CRBSI depends on the following factors: a) early or prompt removal of the catheter; b) documentation of bacteremia, identification of the causative organism and its susceptibility pattern; c) clinical response during the first 48-72 hours of empiric therapy; and d) development of complications. All patients with CRBSI require initial intravenous antimicrobial therapy. The above factors should determine duration of treatment and whether to use a sequential treatment or switch to the oral route. A randomized open trial compared oral combination therapy with a fluoroquinolone plus rifampicin (iv for 24 h, but switched to the oral route as soon as possible) with standard parenteral therapy (flucloxacillin or vancomycin) for bacteremia or deep-seated infections caused by *S. aureus* or catheter-related bacteremia due to drug-susceptible CoNS. Approximately 40% of infections were CRBSI: two-thirds due to *S. aureus* and the rest to CoNS. Clinical and bacteriological cure rates were

similar in both groups, although the median length of hospital stay was significantly shorter in the oral group<sup>214</sup>. A recent study demonstrated that oral linezolid as monotherapy or combination therapy, mostly with rifampicin, is a valid alternative to intravenous therapy for patients with Gram-positive infections, although the number of CRBSI cases was low. Interestingly, none of the patients with CRBSI needed to be readmitted to hospital due to infection or to revert to intravenous antibiotic treatment<sup>215</sup>.

Clinical trials evaluating echinocandins allowed a swift change to oral fluconazole after 7-10 days of intravenous therapy, although specific analyses of the outcome of the *Candida* CRBSI subgroup are not available<sup>216-218</sup>. A recent non-comparative trial of candidemia, in which approximately 50% of the episodes were CRBSI, showed that an early step-down strategy from intravenous anidulafungin to oral azole therapy after 5 days was effective and safe and reduced the length of intravenous treatment<sup>199</sup>.

No specific information is available about the use of oral therapy for Gram-negative CRBSI. Sequential oral therapy can be considered for clinically stable patients without metastatic complications and with negative blood cultures after onset of treatment and removal of the intravenous line.

## RECOMMENDATIONS

1. Sequential oral therapy can be considered in clinically stable patients without metastatic complications and with negative blood cultures after onset of treatment and removal of the intravenous line, if a therapeutic option with high oral bioavailability is available (A-II).
2. In uncomplicated CRBSI caused by fluoroquinolone-susceptible staphylococci, initial intravenous antibiotic treatment may be switched to high-dose oral fluoroquinolones plus rifampicin in order to complete the course of antibiotic therapy if the patient is clinically stable and clearance of bacteremia is documented. Linezolid could be an option if the microorganism involved is fluorquinolone-resistant (A-II).
3. In uncomplicated CRBSI caused by fluoroquinolone-susceptible Gram-negative bacilli, initial intravenous antibiotic treatment may be switched to high-dose oral fluoroquinolones in order to complete the course of

antibiotic therapy if the patient is clinically stable and clearance of bacteremia is documented (A-II).

4. A step-down from an echinocandin or lipid formulation of amphotericin B to oral fluconazole is safe and effective (C-III).

### **Conservative treatment: Antibiotic Lock Therapy (ALT)**

*When is conservative management with antibiotic lock therapy recommended?*

Whenever a conservative treatment is chosen, antibiotic lock therapy should be combined with a systemic antimicrobial. The patient should also be in a stable condition and the causative microorganism considered of low virulence, i.e., CoNS. Metastasis or local septic complications should be excluded before initiating conservative treatment. Table 4 summarizes the indications for catheter removal that make antibiotic lock therapy impossible. Lock therapy involves filling the catheter lumen with a mixture of an anticoagulant and a highly concentrated antibiotic or antiseptic, and temporarily stopping the catheter from flushing. There is no complete agreement at present about the choice of drugs, the duration of each lock period or local treatment<sup>219</sup>. The first randomized, placebo-controlled trial<sup>220</sup> included only CRBSI from long-term VADs, whether tunneled or totally implanted, and compared an antibiotic lock solution containing vancomycin and ceftazidime with placebo, in addition to parenteral antimicrobial treatment in both arms. 174 patients developed bacteremia, 85 of which were catheter-related and 44 patients met the criteria for the modified intention-to-treat analysis. Failure to cure CRBSI occurred in 33% of patients in the antibiotic lock arm and 57% in the placebo group (HR = 0.55, P = 0.10). The study failed to show statistically significant differences and had to be prematurely stopped due to enrolment difficulties. An open, retrospective and prospective non-comparative study of antibiotic lock therapy with vancomycin plus ciprofloxacin or amikacin for 7-16 days showed an 82% cure rate<sup>172</sup>. A prospective non-comparative study of tunneled hemodialysis catheters causing bacteremia combined systemic antimicrobial therapy with lock therapy and cured 40 of 79 patients<sup>221</sup>. When compared with the author's own historical series of patients treated with systemic antibiotics

and immediate catheter withdrawal, salvage therapy was not associated with increased complications or long-term differences in survival.

## RECOMMENDATIONS

1. Conservative treatment should not be prescribed for patients with metastatic or local septic complications (A-II).
2. The use of lock therapy added to systemic antimicrobial agents is systematically recommended for infected catheters that fulfill the criteria for catheter retention: the patient is stable, and the microorganism involved is considered to be of low virulence (i.e., CoNS) (A-I).
3. In stable patients without local or systemic complications, conservative treatment may also be attempted for enterococci, *Corynebacterium* (except *Corynebacterium jeikeium*) and Gram-negatives (consultation with an ID expert is suggested in such cases) (C-III).
4. The use of an antibiotic lock does not preclude the need for systemic antimicrobial therapy (A-I).

*What antibiotics and concentrations of antibiotic lock solutions are recommended?*

The ideal antibiotic for the conservative treatment of CRBSI should have the following characteristics: 1) high activity against biofilms (ability to penetrate and disrupt the biofilm); 2) able to achieve high concentrations (100-1,000 times the MIC of planktonic cells); 3) prolonged stability at room temperature over several days (enables prepared solutions to be stored and the antibiotic lock to be replaced every 24-72 h); 4) compatibility with anticoagulants; 5) safety; 6) low potential for resistance; and 7) cost-effective<sup>222-224</sup>.

There are no randomized studies comparing the effectiveness of different antibiotics used for antimicrobial lock therapy (ALT). The data derive from very heterogeneous observational studies. This is a summary of the most commonly used published evidence.

*Vancomycin* is probably the most widely used antibiotic for ALT at concentrations ranging from 2,000 to 20,000 mg/l, with 2,000 mg/l being the most commonly used<sup>222,225</sup> since the drug precipitates at 10,000 mg/l.

*Vancomycin* at 2,000 mg/l is stable at 37 °C<sup>172</sup>, and can be combined with heparin at 20-100 IU/ml and 4% sodium citrate<sup>226,227</sup>, as well as with other antibiotics such as ciprofloxacin, gentamicin, amikacin and ceftazidime, which facilitates the treatment of polymicrobial infections. In terms of efficacy, 2,000 mg/l vancomycin has been shown to cure 77-93% of infections caused by CoNS<sup>172,225,228</sup>.

*Teicoplanin* has been used at concentrations between 5,000 and 20,000 mg/l, the most commonly used being 10,000 mg/l<sup>172</sup>. It remains stable for 96 hours, with and without associated heparin<sup>229</sup>. It can combine with 100 IU/ml heparin<sup>225</sup>, and with amikacin and gentamicin for polymicrobial infections<sup>230</sup>. Teicoplanin 10,000 mg/l has shown superior efficacy to vancomycin 2,000 mg/l<sup>225</sup>.

*Daptomycin* has been used at concentrations of between 3,500 and 5,000 mg/l<sup>225,231</sup>. Ringer's lactate should be added to the solution. The solution remains stable with and without heparin for 96 h<sup>229</sup>, and can be combined with heparin 100, 400 and 5,000 IU/ml and 4% sodium citrate (daptomycin 5,000 mg/l), as well as with 25% ethanol<sup>232</sup>. In a study of 13 cases, daptomycin 5,000 mg/l achieved an 85% clinical cure rate<sup>233</sup>.

*Ciprofloxacin* at 2,000 mg/l has been used for the treatment of infections caused by Gram-negative bacilli, including *Pseudomonas* spp.<sup>172,228,234</sup>, reaching success rates of 95% in selected populations<sup>223</sup>. The solution remains stable for 10 days at 37 °C. It precipitates with heparin<sup>230</sup>, but maintains its efficacy<sup>172</sup>.

*Amikacin* has been widely used at concentrations of between 1,500 and 60,000 mg/l, the most frequently used being 2,000 mg/l<sup>222</sup>. It can be administered with heparin and its efficacy is high, above 90%<sup>222</sup>.

Other antibiotics used as ALT for the conservative treatment of CRBSI are gentamicin (2,000-5,000 mg/l), cefazolin (5,000-10,000 mg/l), and ceftazidime (500-10,000 mg/l)<sup>222,223</sup>.

## RECOMMENDATION

1. The most frequently used antibiotics for conservative treatment of CRBSI using ALT are vancomycin 2,000 mg/l, teicoplanin 10,000 mg/l,

daptomycin 5,000 mg/l, ciprofloxacin 2,000 mg/l, and amikacin 2,000 mg/l (B-I).

*How should antibiotic lock therapy be performed?*

Lock solutions reported in the literature with potential use in clinical practice are described in Table 5. Although many published studies on the effectiveness of ALT are available, few describe the technique in detail<sup>104,222–224</sup>.

*ALT preparation and storage.* The solution should be prepared under sterile conditions, ideally in the Pharmacy Service. These solutions have prolonged stability and can be prepared every 3-7 days and stored at 4 °C until required for use (Table 6).

*Volume of the lock solution.* Most studies use between 2 and 3 ml in tunneled catheters and 3 to 5 ml in totally implantable ports<sup>172,234–239</sup>. However, considering the great variability of catheters used, the exact catheter volume specified in the instructions provided by the manufacturer should be instilled<sup>234,236,240</sup>.

*Replacement of ALT solutions.* Before using the catheter or replacing the ALT solution, the previous ALT should be removed<sup>172,221,237,240–243</sup> to prevent the risk of adverse events associated with the rapid infusion of antibiotics at high concentrations and the cleaning of the catheter lumen occurring by entrainment.

*Length of ALT.* The optimal duration of ALT is not known. In most recent studies, ALT was given for 10-14 days<sup>172,220,228,233,234,238,242–244</sup>, although a shorter treatment duration may be efficacious, especially for Gram-negative infections<sup>172,244</sup>.

*Frequency of ALT.* The frequency of ALT replacement has not been established. It is usually performed every 24-72 h and adapted to the use and needs of the infected line. In hemodialysis patients, ALT is replaced after each hemodialysis session<sup>172,233–235,240,245</sup>. If more frequent use of the catheter is needed, the lock is replaced every 24 h<sup>220,228,244</sup>.

*Catheter use.* Ideally, the catheter should not be used while the ALT solution is in place. However, for patients receiving parenteral nutrition or those with few or no other venous access options, ALT and catheter may be alternated. In such cases, a minimum of 8-12 h a day is

recommended<sup>220,228,234,244,246</sup>. If the catheter has more than one lumen, all should be treated.

*Systemic treatment.* Bacteremic patients should be treated with systemic antibiotics for a period of 7-14 days<sup>172,228,234,236,242,244,246</sup>. This period may be shorter for CoNS infections<sup>25</sup>.

## RECOMMENDATION

1. An ALT solution should be prepared under sterile conditions. It should be infused after removing the previous dose and the exact volume of the catheter lumen should be infused. The recommended duration of ALT is 10 to 14 days. The ALT solution must remain in the catheter lumen for a minimum of 12 h a day and should be replaced every 24-72 h (B-I).

### *What non-antibiotic substances could be used for lock therapy?*

Apart from the antibiotics described above, other non-antibiotic substances have been used for lock therapy.

*Ethanol* (with activity against bacteria and fungi) has been used for the prevention of CRBSI in long-term CVCs. In several therapeutic randomized trials, a 70% ethanol lock showed a significant decrease in the rate of CRBSI compared with saline or heparin solutions<sup>167,247-250</sup>. It is important to note that these studies also reported severe adverse events, such as flushes, dizziness, doubling of liver enzymes, catheter rupture or thrombosis, leading to interruption of therapy in some patients<sup>250</sup>. In two retrospective studies and one randomized study including more than 100 patients that used 70% ethanol lock therapy for the treatment of CRBSI, cure rates were reported in 62-91% of cases with no significant adverse events<sup>167,251,252</sup>.

*Taurolidine*, like 70% ethanol, has been evaluated in several large randomized studies of the prevention of CRBSI. Taurolidine, mostly compared with heparin, was associated with significant reductions in the rate of bloodstream infections. In a retrospective study of 11 cancer patients treated for CRBSI with a taurolidine lock, only three relapsed, but were eventually cured with another-taurolidine lock<sup>253</sup>.

*EDTA and citrate.* These two chelators are able to disrupt biofilm, thus increasing antimicrobial activity. Several in vitro studies have demonstrated the proven anti-biofilm effect of EDTA alone or in combination with gentamicin or minocycline plus 25% ethanol<sup>104,222</sup>. Further clinical studies are needed to establish the role of these two substances<sup>254</sup>.

#### ***RECOMMENDATION***

1. 70% ethanol and taurolidine locks might be used for the conservative treatment of CRBSI. However, there is no evidence to advocate for their routine use (B-I).

#### *What are the criteria for failure of conservative management?*

The criteria for failure of conservative treatment of CRBSI are based on the patient's worsening clinical condition, persistence of infection, and catheter dysfunction or removal<sup>85,166,172,228,255-257</sup>.

It does not seem to be ethical to perform a randomized clinical trial about retaining infected catheters for certain critical clinical conditions. Catheter dysfunction requiring replacement is also considered failure of conservative treatment. In most reports, catheters were removed for ongoing sepsis, defined as persistent fever or bacteremia after 48-72 hours of adequate therapy, or if metastatic septic complications like endocarditis or osteomyelitis, or local complications, such as venous thrombosis, septic phlebitis or tunnelitis, occurred. Conservative management is contraindicated for some of these complications, which should be followed by sequential blood cultures drawn both from a peripheral vein and through the catheter to monitor the clinical course of CRBSI<sup>228,255</sup>.

Definitions of efficacy or failure of conservative management in clinical studies or clinical practice sometimes include late relapse of infection<sup>257</sup>.

#### ***RECOMMENDATION***

1. Any clinical condition or catheter dysfunction prompting catheter removal should be considered failure of conservative management (A-I).

## Management of local complications

### *How should insertion site infection be managed?*

Short-term catheters (peripheral venous, non-tunneled CVCs and arterial catheters) with erythema, pain, warmth, induration and/or purulent drainage within 2 cm of the catheter exit site should be removed in spite of absence of concomitant bacteremia<sup>25,258</sup>. Any exudate at the insertion site should be submitted for Gram staining, routine culture, and fungal culture when assessing immunocompromised patients<sup>25</sup>.

In uncomplicated infections involving long-term catheters (tunneled CVCs, hemodialysis), defined as absence of fever, positive blood cultures or purulence, cultures of any drainage from the exit site should be obtained, together with peripheral blood cultures<sup>259</sup>. Under these circumstances, topical application of an antibiotic ointment at the insertion site may be considered, based on exit-site culture results. If the infection does not resolve or purulent exudate develops, systemic antibiotics should be administered. If clinical signs of infection persist after 48-72 hours of appropriate antimicrobial therapy, the catheter should be removed<sup>25,259</sup>. The topical application of antibiotic ointment to the insertion site following catheter removal is not recommended<sup>260</sup>.

### **RECOMMENDATIONS**

1. For peripheral venous catheters, catheter removal is mandatory if there is local pain, induration, erythema or exudate (A-I).
2. For non-tunneled CVCs, the presence of erythema or purulence at the catheter insertion site requires immediate catheter removal (B-II).
3. For uncomplicated exit site infections with long-term catheters, a conservative approach with topical antimicrobial agents should first be attempted. In cases of topical treatment failure, systemic antibiotics should be administered (B-III).
4. Persistence of clinical signs of infection beyond 72 hours of conservative management requires removal of the catheter (B-II).

### *How should tunnelitis be managed?*

Tunnel infection in a long-term catheter, other than a hemodialysis catheter, should be managed with catheter removal, drainage and incision, if indicated, and 7-10 days of systemic antibiotic therapy in the absence of concomitant bacteremia or candidemia<sup>25,261</sup>. If systemic antibiotics fail, the catheter should be removed. In the setting of tunnel infection with fever, catheter removal is the first option, together with adequate antibiotic therapy<sup>68,262</sup>.

Taking a conservative approach, failure rates of more than 50% have been reported and, in this case, are associated with increased cost and workload<sup>222,263</sup>.

#### **RECOMMENDATIONS**

1. Patients with tunnelitis not associated with a hemodialysis catheter require catheter removal, incision and drainage, if indicated, and 7-10 days of systemic antimicrobial therapy in the absence of concomitant bacteremia or candidemia (A-II).
2. For tunnelitis without fever in hemodialysis catheters, systemic antibiotic therapy may be attempted first (A-II). In tunnel infection with fever, catheter removal is the first therapeutic option together with systemic antimicrobial therapy (A-II).
3. Tunnelitis conservative management is associated with higher failure rates (B-II).

*How should a local infection associated with a port reservoir be managed?*

A complicated local infection of a venous access device is defined as infection of the tunnel or port pocket with erythema or induration (more than 2 cm), purulent collection, skin necrosis and spontaneous rupture and drainage. A stitch abscess is a focal area of purulence or redness around a suture. The single offending stitch can usually be removed without further consequences and should not be confused with a port infection<sup>263</sup>. Management of a port reservoir infection requires removal of the port, drainage of affected tissues and administration of antibiotic therapy for 7-10 days in the absence of concomitant bacteremia or fungemia<sup>25,222,224</sup>. Depending on the severity of the infection, the insertion wound may be sutured following removal of the port, or, if there is

significant drainage, exudate or pus, the wound should be left open and packed with iodoform gauze to heal by secondary intention<sup>263</sup>. Surgical removal of a venous access port is frequently a challenge to management and is initially avoided. Alternately, it may be possible to salvage the port with a conservative treatment by stopping use of the device and initiating a combination of antibiotic lock therapy and systemic antibiotic treatment<sup>104</sup>. Most infections are associated with intraluminal colonization and it is necessary therefore to administer a high concentration of antimicrobial solution to try and sterilize the device<sup>264</sup>.

## RECOMMENDATIONS

1. In the presence of signs of local inflammation at the reservoir pocket, the port must be removed, the affected tissue drained, and systemic antibiotic therapy started (A-II).
2. If a conservative strategy is the only option, a combination of systemic antibiotics and antibiotic lock therapy should be prescribed, bearing in mind that this approach is associated with a high failure rate (B-II).

## Patient follow-up

*In which patients and when should a follow-up blood culture be taken?*

Persistent bloodstream infection is defined as the presence of viable pathogens in the blood after 3 days of appropriate antimicrobial treatment. Persistent bacteremia with certain pathogens has been associated with the development of complications and worse outcomes<sup>265</sup>. Patients with persistent bacteremia due to *Staphylococcus aureus* present higher relapse rates and related mortality within 12 weeks of a bacteremia episode<sup>266</sup>. The most robust predictor of complicated *S. aureus* bacteremia was positive follow-up blood cultures at 48 to 96 hours after the first positive blood culture<sup>267</sup>. In a study in which blood cultures were taken every 3 days following a positive blood culture for *S. aureus*, the rate of septic metastasis for bacteremia lasting <3 days was 5%, increasing to 25% in patients with ≥10 days of documented bacteremia<sup>268</sup>.

Persistent candidemia has also been associated with a high mortality rate. Kim et al. reported that persistent candidemia increased the risk of mortality, with adjusted hazard ratio of 2.5 (95% CI = 1.33-4.72). As antifungal

therapy should be continued until 14 days after the first negative blood culture, follow-up blood cultures should be obtained daily until the first negative blood culture<sup>269</sup>.

## RECOMMENDATIONS

1. Follow-up blood cultures should be taken from all patients with *S. aureus* or *Candida* spp. CRBSI (A-II).
2. In patients with *S. aureus* CRBSI, we recommend that follow-up blood cultures should be obtained every 72 hours until the first negative result (A-II).
3. Control blood cultures in CRBSI due to *Candida* spp. should be obtained every 48 hours until the first negative blood culture (A-II).
4. For other causative microorganisms of CRBSI and if catheter salvage is attempted, follow-up blood cultures should be obtained 72 hours after starting appropriate antibiotic therapy. If persistent bacteremia is documented, catheter removal is required (B-II).
5. It is not necessary to routinely perform follow-up blood cultures in patients with CRBSI due to microorganisms other than *S. aureus* or *Candida* spp. if the catheter has been withdrawn (A-II).

### *When should echocardiography be performed?*

The risk of underlying infective endocarditis in bacteremic patients depends mainly on the etiologic agent causing the bacteremia and the predisposing conditions of the patient. Patients with *S. aureus* bacteremia are at high risk for IE, which is frequently not clinically evident or suspected.

The absence of valvular risk (no valvular disease, either previously or diagnosed at the moment of SAB), together with a clinical and microbiological response (negative blood cultures) to therapy within the first 72 h of catheter removal and initiation of adequate antibiotic therapy were associated with a favorable outcome (absence of complications or relapse) in more than 95% of patients who received treatment for at least 14 days after negative blood cultures. A recent systematic review<sup>270</sup> of 9 observational studies with sample sizes ranging from 98 to 877 patients<sup>271,272</sup> reported an incidence of 2% to 14%

detected by transthoracic echocardiography (TTE) and 14% to 25% by transesophageal echocardiography (TEE). Clinical findings and TTE were poorly predictive of subsequent TEE findings. In a high proportion of cases, IE was not suspected on clinical grounds and 15% of cases were reclassified by TEE<sup>273</sup>.

Currently, 6 studies<sup>274-279</sup> suggest that, due to the very low risk for IE, TEE can safely be avoided in patients without any of the following risk factors: prolonged bacteremia, hemodialysis, community-acquisition, metastatic foci of infection, immunologic or embolic phenomena, intravenous drug abuse (IVDA), implantable CVC, intracardiac device), prosthetic valve, previous IE or cardiac structural abnormality.

In patients with proven enterococcal CRBSI, the requirement to systematically rule out endocarditis is currently under discussion. Estimates of endocardial involvement vary and are not well addressed in the medical literature. In a recent study of 1,515 patients with enterococcal BSI (E-BSI), 65 (4.29%) had enterococcal endocarditis, representing 16.7% of patients with E-BSI who underwent TTE and 35.5% with E-BSI who underwent TEE. A bedside score totalling 12 points for predicting enterococcal endocarditis was developed, the NOVA score, based on the number of positive blood cultures, origin of the bacteremia, prior valve disease and the auscultation of a heart murmur. A NOVA score of less than 5 points, which corresponded to 14 to 27% of patients with enterococcal bacteremia, identified a subgroup at very low risk for enterococcal endocarditis who could avoid TEE<sup>280</sup>.

The incidence of endocarditis in patients with candidemia has been assessed less frequently. In a recent study, endocarditis was detected in 2.9 % of patients with candidemia using TTE and in 11.5% undergoing TEE<sup>281</sup>.

## RECOMMENDATIONS

1. TEE should be performed in the vast majority of patients with *Staphylococcus aureus* bacteraemia. TEE is not necessary or can be delayed in patients without the following risk factors: prolonged bacteraemia, hemodialysis, metastatic foci of infection, IVDA, implantable CVC, intracardiac device, prosthetic valve, previous IE or cardiac structural abnormality (A-II).

2. The need for TEE in episodes of CRBSI caused by other pathogens should be individualized. This panel considers that IE should be ruled out in all patients with persistent bacteremia (or fungemia) (C-III). *Enterococcus* spp. and *Candida* spp. pathogens are associated with a high risk of developing endocarditis.

*What is the diagnosis and management for suppurative thrombophlebitis?*

Suppurative thrombophlebitis refers to venous thrombosis associated with infection and bacteremia. The pathogenesis of catheter-related thrombosis results from the activation of coagulation pathways by the foreign material in the bloodstream, vascular endothelial damage and endothelial cell activation<sup>25,282</sup>. Infection may also stimulate thrombus formation by aggravating coagulation abnormalities. The presence of a thrombus mass around the catheter increases the risk for microbial colonization and bacteremia<sup>283</sup>. CRBSI and thrombosis appear therefore to have a bidirectional relationship.

Suppurative thrombophlebitis combines the signs and symptoms of infection from the thrombosis with the dysfunction of the involved catheter. Microbiological and radiologic tests are necessary to confirm the diagnosis. Thrombosis should be confirmed with ultrasonography (70-100% sensitivity and 93% specificity), high-resolution computed tomography or phlebography. Limited experience with magnetic resonance imaging suggests that it may also be useful in the diagnosis of thrombophlebitis<sup>25,284</sup>. Recent data indicate that a proactive search for thrombosis in the setting of suspected CRBSI is a safe and effective strategy that enables the catheter to be preserved in neutropenic patients if thrombosis is ruled out<sup>284</sup>.

Management of thrombophlebitis requires catheter removal, prolonged antimicrobial treatment of at least 4-6 weeks, surgery (drainage of abscess and/or venous resection) if a collection is detected or the clinical response is not achieved, and thrombus treatment (anticoagulation or even thrombolytic therapy)<sup>283</sup>. Venous resection has not been shown to be superior to conservative management (including involvement of superficial veins). There is insufficient clinical evidence available to support the use of systemic anticoagulation, while systemic thrombolysis has only been used in specific

cases<sup>285–287</sup>.

Follow-up of thrombophlebitis should include clinical data, sequential ultrasonography and possibly biomarkers. Procalcitonin (PCT) will probably be more effective for detecting non-responding CRBSI potentially complicated by the associated thrombophlebitis, in which case urgent catheter removal would be required<sup>288</sup>.

## RECOMMENDATIONS

1. Suppurative thrombophlebitis should be ruled out in all episodes of CRBSI with persistent bacteraemia (A-II).
2. Confirmed diagnosis, mainly by ultrasonography, should be followed by catheter withdrawal, prolonged antibiotic treatment and an individualized assessment of the need for anticoagulation (A-II).

### *When can a new catheter be inserted?*

There is no scientific evidence indicating how long the patient should wait before a new catheter can be safely inserted after an episode of CRBSI. The placement of a new catheter will obviously be determined by the need for vascular access. Patients with short-term catheters for vital continuous infusion medications usually require immediate insertion of a new catheter. If it is feasible to wait, PCT may be useful for monitoring the response to therapy. In a small prospective study including 26 patients with CRBSI, a serum PCT concentration of  $>1.5$  ng/ml on day 3 of therapy was associated with lack of response to therapy (sensitivity 70%, specificity 68.7%;  $p = 0.028$ ), while a decrease in serum PCT concentrations of at least 1.00 ng/ml from day 1 to day 2 and of 0.30 ng/ml from day 2 to day 3 indicated response to therapy ( $p = 0.037$  and 0.017, respectively).<sup>288</sup>

The clinical situation of patients with long-term catheters, implantable venous access catheters (IVAC) or tunneled catheters may allow for a time interval before a new catheter is placed. Experts recommend waiting for resolution of clinical signs or even microbiological eradication (negative blood cultures). The only available study is a small case-control evaluation, which showed no differences between removal with simultaneous reimplantation in

13 patients and delayed reimplantation (mean 14 days) in 21. There were two cases of re-infection in the simultaneous reimplantation group (15.4%) and one case in the delayed reimplantation group (4.8%)<sup>289</sup>. Non-randomized studies of hemodialysis-associated CRBSI have shown heterogeneous results<sup>166</sup>.

## **RECOMMENDATIONS**

1. Although there is a clear lack of scientific evidence, it seems advisable to wait, if feasible, before placing a new catheter after an episode of CRBSI. The waiting period should be determined by the resolution of signs and symptoms. If a patient urgently needs vascular access, a catheter should be inserted without delay (C-III).
2. Insertion of a new catheter after a diagnosis of CRBSI is always possible if the patient's clinical condition dictates the need for a new vascular access (A-III).

## **Conflict of interest statement**

Jaime Esteban has participated in counseling and lectures at meetings sponsored by Laboratorios Leti SL in the last year, as well as received grants for research and teaching from laboratories Pfizer, Sysmex, Angelini and bioMérieux.

Paula Ramírez has participated in counseling and lectures at meetings sponsored by Pfizer, MSD, Astellas, Gilead and Otsuka in the last year, as well as received grants for research and teaching at Otsuka laboratories.

José Luis del Pozo has lectured at meetings sponsored by Pfizer, MSD and Angelini Laboratories.

Miguel Salavert has participated in counseling and lectures at meetings sponsored by MSD, Pfizer, Gilead, Astellas Ph and Angelini in the last year, as well as received grants for research and teaching from Janssen and ViiV laboratories

José Ramón Paño has participated in counseling and lectures at meetings sponsored by Janssen, Gilead and MSD in the last year.

José Garnacho-Montero has participated in conferences sponsored by MSD and Astellas.

Emilio Bouza has participated in advisory services and lectures sponsored by MSD, Pfizer and Astellas in the last year.

The rest of the authors declare that they have no conflicts of interest.

## References

1. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. Estudio EPINE-EPPS 2015. Informe global de España. [Internet]. [cited 2016 Nov 19]. Available from: <http://hws.vhebron.net/epine/Descargas/EPINE%202015%20INFORME%20GLOBAL%20DE%20ESPA%C3%91A%20RESUMEN.pdf>.
2. Fortún J. [Infections related to intravascular devices used for infusion therapy]. *Enferm Infecc Microbiol Clin.* 2008 Mar;26(3):168–74.
3. Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. *Clin Microbiol Infect.* 2010 Sep;16(9):1408–13.
4. Riu M, Terradas R, Sala M, Comas M, Knobel H, Grau S, et al. [Costs associated with nosocomial bacteraemias in a University Hospital]. *Enferm Infecc Microbiol Clin.* 2012 Mar;30(3):137–42.
5. Olaechea PM, Palomar M, Álvarez-Lerma F, Otal JJ, Insausti J, López-Pueyo MJ, et al. Morbidity and mortality associated with primary and catheter-related bloodstream infections in critically ill patients. *Rev Esp Quimioter.* 2013 Mar;26(1):21–9.
6. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. *Lancet Infect Dis.* 2007 Oct;7(10):645–57.
7. León C, Ariza J, SEIMC, SEMICYUC. [Guidelines for the treatment of short-term intravascular catheter-related infections in adults; SEIMC-SEMICYUC Consensus Conference]. *Enferm Infecc Microbiol Clin.* 2004 Feb;22(2):92–101.
8. Mandell, Douglas, and Bennett's. *Infectious Diseases*. 8th ed. Philadelphia: Saunders; 2015.
9. Ye R, Zhao L, Wang C, Wu X, Yan H. Clinical characteristics of septic pulmonary embolism in adults: a systematic review. *Respir Med.* 2014 Jan;108(1):1–8.
10. Raad I, Narro J, Khan A, Tarrand J, Vartivarian S, Bodey GP. Serious complications of vascular catheter-related *Staphylococcus aureus*

bacteremia in cancer patients. *Eur J Clin Microbiol Infect Dis.* 1992 Aug;11(8):675–82.

11. Ghanem GA, Boktour M, Warneke C, Pham-Williams T, Kassis C, Bahna P, et al. Catheter-related *Staphylococcus aureus* bacteremia in cancer patients: high rate of complications with therapeutic implications. *Medicine (Baltimore).* 2007 Jan;86(1):54–60.
12. Washington JA. Blood cultures: principles and techniques. *Mayo Clin Proc.* 1975 Feb;50(2):91–8.
13. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? *J Clin Microbiol.* 2007 Nov;45(11):3546–8.
14. Cockerill FR, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, et al. Optimal testing parameters for blood cultures. *Clin Infect Dis.* 2004 Jun 15;38(12):1724–30.
15. M47-A: Principles and Procedures for Blood Cultures; Approved Guideline - M47A\_sample.pdf [Internet]. [cited 2016 Jun 28]. Available from: [http://shop.clsi.org/site/Sample\\_pdf/M47A\\_sample.pdf](http://shop.clsi.org/site/Sample_pdf/M47A_sample.pdf)
16. Garcia RA, Spitzer ED, Beaudry J, Beck C, Dibiasi R, Gilleeney-Blabac M, et al. Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections. *Am J Infect Control.* 2015 Nov 1;43(11):1222–37.
17. Falagas ME, Kazantzi MS, Bliziotis IA. Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. *J Med Microbiol.* 2008 Jan;57(Pt 1):1–8.
18. Boyce JM, Nadeau J, Dumigan D, Miller D, Dubowsky C, Reilly L, et al. Obtaining blood cultures by venipuncture versus from central lines: impact on blood culture contamination rates and potential effect on central line-associated bloodstream infection reporting. *Infect Control Hosp Epidemiol.* 2013 Oct;34(10):1042–7.
19. Dawson S. Blood culture contaminants. *J Hosp Infect.* 2014 May;87(1):1–10.
20. Mimoz O, Karim A, Mercat A, Cosseron M, Falissard B, Parker F, et al. Chlorhexidine compared with povidone-iodine as skin preparation before blood culture. A randomized, controlled trial. *Ann Intern Med.* 1999 Dec 7;131(11):834–7.
21. Suwanpimolkul G, Pongkumpai M, Suankratay C. A randomized trial of 2% chlorhexidine tincture compared with 10% aqueous povidone-iodine for venipuncture site disinfection: Effects on blood culture contamination rates. *J Infect.* 2008 May;56(5):354–9.

22. Kiyoyama T, Tokuda Y, Shiiki S, Hachiman T, Shimasaki T, Endo K. Isopropyl alcohol compared with isopropyl alcohol plus povidone-iodine as skin preparation for prevention of blood culture contamination. *J Clin Microbiol*. 2009 Jan;47(1):54–8.
23. Caldeira D, David C, Sampaio C. Skin antiseptics in venous puncture-site disinfection for prevention of blood culture contamination: systematic review with meta-analysis. *J Hosp Infect*. 2011 Mar;77(3):223–32.
24. Washer LL, Chenoweth C, Kim H-W, Rogers MAM, Malani AN, Riddell J, et al. Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. *Infect Control Hosp Epidemiol*. 2013 Jan;34(1):15–21.
25. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Jul 1;49(1):1–45.
26. Wilson ML, Weinstein MP, Reller LB. Laboratory Detection of Bacteremia and Fungemia. In: Jorgensen JH, Pfaller MA editors. *Manual of Clinical Microbiology*. 11th ed. Washington, DC; 2015. p. 15–28.
27. Procedimientos en Microbiología Clínica - seimc-procedimientomicrobiologia1a.pdf. Available from: [https://www.seimc.org/contenidos/documentoscientificos/procedimientos\\_microbiologia/seimc-procedimientomicrobiologia1a.pdf](https://www.seimc.org/contenidos/documentoscientificos/procedimientos_microbiologia/seimc-procedimientomicrobiologia1a.pdf)
28. Robinson JL. Sensitivity of a blood culture drawn through a single lumen of a multilumen, long-term, indwelling, central venous catheter in pediatric oncology patients. *J Pediatr Hematol Oncol*. 2002 Jan;24(1):72–4.
29. Guembe M, Rodríguez-Créixems M, Sánchez-Carrillo C, Pérez-Parra A, Martín-Rabadán P, Bouza E. How many lumens should be cultured in the conservative diagnosis of catheter-related bloodstream infections? *Clin Infect Dis*. 2010 Jun 15;50(12):1575–9.
30. Cuellar-Rodriguez J, Connor D, Murray P, Gea-Banacloche J, National Institutes of Health (NIH), Bethesda, MD, USA. Discrepant results from sampling different lumens of multilumen catheters: the case for sampling all lumens. *Eur J Clin Microbiol Infect Dis*. 2014 May;33(5):831–5.
31. Fenner L, Widmer AF, Straub C, Frei R. Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period. *J Clin Microbiol*. 2008 Jul;46(7):2432–4.
32. BSI Event Protocol - 4PSC\_CLABScurrent.pdf [Internet]. Available from: [http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC\\_CLABScurrent.pdf](http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf)
33. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology,

and outcome of bacteremia and fungemia in adults. *Clin Infect Dis*. 1997 Apr;24(4):584–602.

34. Stevenson LG, Drake SK, Murray PR. Rapid identification of bacteria in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol*. 2010 Feb;48(2):444–7.
35. Ferreira L, Sánchez-Juanes F, Porras-Guerra I, García-García MI, García-Sánchez JE, González-Buitrago JM, et al. Microorganisms direct identification from blood culture by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Clin Microbiol Infect*. 2011 Apr;17(4):546–51.
36. Chen JHK, Ho P-L, Kwan GSW, She KKK, Siu GKH, Cheng VCC, et al. Direct bacterial identification in positive blood cultures by use of two commercial matrix-assisted laser desorption ionization-time of flight mass spectrometry systems. *J Clin Microbiol*. 2013 Jun;51(6):1733–9.
37. Martiny D, Debaugnies F, Gateff D, Gérard M, Aoun M, Martin C, et al. Impact of rapid microbial identification directly from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry on patient management. *Clin Microbiol Infect*. 2013 Dec;19(12):E568-581.
38. Rodríguez-Sánchez B, Sánchez-Carrillo C, Ruiz A, Marín M, Cercenado E, Rodríguez-Créixems M, et al. Direct identification of pathogens from positive blood cultures using matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. *Clin Microbiol Infect*. 2014 Jul;20(7):O421-427.
39. Rodríguez C, Bratos A, Merino E, Ezpeleta C. [Use of MALDI-TOF in the rapid diagnosis of sepsis]. *Enferm Infecc Microbiol Clin*. 2016 Jun;34 Suppl 2:19–25.
40. Scott JS, Sterling SA, To H, Seals SR, Jones AE. Diagnostic performance of matrix-assisted laser desorption ionisation time-of-flight mass spectrometry in blood bacterial infections: a systematic review and meta-analysis. *Infect Dis (Lond)*. 2016 Jul;48(7):530–6.
41. Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. *Clin Infect Dis*. 2013 Nov;57(9):1237–45.
42. Catton JA, Dobbins BM, Kite P, Wood JM, Eastwood K, Sugden S, et al. In situ diagnosis of intravascular catheter-related bloodstream infection: a comparison of quantitative culture, differential time to positivity, and endoluminal brushing. *Crit Care Med*. 2005 Apr;33(4):787–91.

43. Bouza E, Alvarado N, Alcalá L, Pérez MJ, Rincón C, Muñoz P. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. *Clin Infect Dis.* 2007 Mar 15;44(6):820–6.
44. Blot F, Nitengberg G, Chachaty E, Raynard B, Germann N, Antoun S, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. *Lancet.* 1999 Sep 25;354(9184):1071–7.
45. Blot F, Schmidt E, Nitengberg G, Tancrède C, Leclercq B, Laplanche A, et al. Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. *J Clin Microbiol.* 1998 Jan;36(1):105–9.
46. Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. *Ann Intern Med.* 2004 Jan 6;140(1):18–25.
47. Rijnders BJ, Verwaest C, Peetermans WE, Wilmer A, Vandecasteele S, Van Eldere J, et al. Difference in time to positivity of hub-blood versus nonhub-blood cultures is not useful for the diagnosis of catheter-related bloodstream infection in critically ill patients. *Crit Care Med.* 2001 Jul;29(7):1399–403.
48. Blot F. Why should paired blood cultures not be useful for diagnosing catheter-related bacteraemia in critically ill patients? *Crit Care Med.* 2002 Jun;30(6):1402–3.
49. Bouza E, Alcalá L, Muñoz P, Martín-Rabadán P, Guembe M, Rodríguez-Créixems M, et al. Can microbiologists help to assess catheter involvement in candidaemic patients before removal? *Clin Microbiol Infect.* 2013 Feb;19(2):E129-35.
50. Kaasch AJ, Rieg S, Hellmich M, Kern WV, Seifert H. Differential time to positivity is not predictive for central line-related *Staphylococcus aureus* bloodstream infection in routine clinical care. *J Infect.* 2014 Jan;68(1):58–61.
51. Park K-H, Lee MS, Lee S-O, Choi S-H, Sung H, Kim M-N, et al. Diagnostic usefulness of differential time to positivity for catheter-related candidemia. *J Clin Microbiol.* 2014 Jul;52(7):2566–72.
52. Hakim A, Deplano A, Maes N, Kentos A, Rossi C, Struelens MJ. Polyclonal coagulase-negative staphylococcal catheter-related bacteraemia documented by molecular identification and typing. *Clin Microbiol Infect.* 1999 Apr;5(4):224–7.
53. Rijnders BJ, Van Wijngaerden E, Van Eldere J, Peetermans WE. Polyclonal *Staphylococcus epidermidis* intravascular catheter-related infections. *Clin Microbiol Infect.* 2001 Jul;7(7):388–91.

54. García de Viedma D, Martín Rabadán P, Díaz M, Cercenado E, Bouza E. Heterogeneous antimicrobial resistance patterns in polyclonal populations of coagulase-negative staphylococci isolated from catheters. *J Clin Microbiol*. 2000 Apr;38(4):1359–63.
55. Yagupsky P, Nolte FS. Quantitative aspects of septicemia. *Clin Microbiol Rev*. 1990 Jul;3(3):269–79.
56. Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. *Clin Microbiol Infect*. 2002 May;8(5):265–74.
57. Planes AM, Calleja R, Bernet A, Campins-Martí M, Almirante B, Pumarola T, et al. Evaluation of the usefulness of a quantitative blood culture in the diagnosis of catheter-related bloodstream infection: Comparative analysis of two periods (2002 and 2012). *Enferm Infecc Microbiol Clin*. 2016 Oct;34(8):484–9.
58. Flynn PM, Sheneb JL, Barrett FF. Differential quantitation with a commercial blood culture tube for diagnosis of catheter-related infection. *J Clin Microbiol*. 1988 May;26(5):1045–6.
59. Capdevila JA, Planes AM, Palomar M, Gasser I, Almirante B, Pahissa A, et al. Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis. *Eur J Clin Microbiol Infect Dis*. 1992 May;11(5):403–7.
60. Quilici N, Audibert G, Conroy MC, Bollaert PE, Guillemin F, Welfringer P, et al. Differential quantitative blood cultures in the diagnosis of catheter-related sepsis in intensive care units. *Clin Infect Dis*. 1997 Nov;25(5):1066–70.
61. Chatzinikolaou I, Hanna H, Hachem R, Alakech B, Tarrand J, Raad I. Differential quantitative blood cultures for the diagnosis of catheter-related bloodstream infections associated with short- and long-term catheters: a prospective study. *Diagn Microbiol Infect Dis*. 2004 Nov;50(3):167–72.
62. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. *Ann Intern Med*. 2005 Mar 15;142(6):451–66.
63. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. *Nephrol Dial Transplant*. 2006 Apr;21(4):1024–31.
64. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S, et al. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. *Am J Infect Control*. 2004 May;32(3):155–60.
65. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. *Kidney Int*. 2000 Dec;58(6):2543–5.

66. Lafrance J-P, Rahme E, Lelorier J, Iqbal S. Vascular access-related infections: definitions, incidence rates, and risk factors. *Am J Kidney Dis.* 2008 Nov;52(5):982–93.
67. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. *Am J Kidney Dis.* 2004 Nov;44(5):779–91.
68. Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, et al. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). *NDT Plus.* 2010 Jan 6;3(3):234–46.
69. Allon M. Treatment guidelines for dialysis catheter-related bacteremia: an update. *Am J Kidney Dis.* 2009 Jul;54(1):13–7.
70. Kite P, Dobbins BM, Wilcox MH, McMahon MJ. Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal. *Lancet.* 1999 Oct 30;354(9189):1504–7.
71. Dobbins BM, Kite P, Catton JA, Wilcox MH, McMahon MJ. In situ endoluminal brushing: a safe technique for the diagnosis of catheter-related bloodstream infection. *J Hosp Infect.* 2004 Nov;58(3):233–7.
72. Kite P, Dobbins BM, Wilcox MH, Fawley WN, Kindon AJ, Thomas D, et al. Evaluation of a novel endoluminal brush method for in situ diagnosis of catheter related sepsis. *J Clin Pathol.* 1997 Apr;50(4):278–82.
73. Catton JA, Dobbins BM, Kite P, Wood JM, Eastwood K, Sugden S, et al. In situ diagnosis of intravascular catheter-related bloodstream infection: a comparison of quantitative culture, differential time to positivity, and endoluminal brushing. *Crit Care Med.* 2005 Apr;33(4):787–91.
74. Millar MR, Johnson G, Wilks M, Skinner R, Stoneham S, Pizer B, et al. Molecular diagnosis of vascular access device-associated infection in children being treated for cancer or leukaemia. *Clin Microbiol Infect.* 2008 Mar;14(3):213–20.
75. Millar M, Zhou W, Skinner R, Pizer B, Hennessy E, Wilks M, et al. Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer. *Health Technol Assess.* 2011 Feb;15(7):1–114.
76. Müller-Premru M, Cernelc P. Molecular epidemiology of catheter-related bloodstream infections caused by coagulase-negative staphylococci in haematological patients with neutropenia. *Epidemiol Infect.* 2004 Oct;132(5):921–5.
77. Dark P, Wilson C, Blackwood B, McAuley DF, Perkins GD, McMullan R, et al. Accuracy of LightCycler(R) SeptiFast for the detection and identification of pathogens in the blood of patients with suspected sepsis: a systematic review protocol. *BMJ Open.* 2012;2(1):e000392.

78. Pasqualini L, Mencacci A, Leli C, Montagna P, Cardaccia A, Cenci E, et al. Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. *J Clin Microbiol*. 2012 Apr;50(4):1285–8.
79. Torres-Martos E, Pérez-Ruiz M, Pedrosa-Corral I, Peña-Caballero M, Jiménez-Valera MM, Pérez-Ramírez MD, et al. [Evaluation of the LightCycler® SeptiFast test in newborns and infants with clinical suspicion of sepsis]. *Enferm Infect Microbiol Clin*. 2013 Jul;31(6):375–9.
80. Biendo M, Mammeri H, Pluquet E, Guillon H, Rousseau F, Canarelli B, et al. Value of Xpert MRSA/SA blood culture assay on the Gene Xpert® Dx System for rapid detection of *Staphylococcus aureus* and coagulase-negative staphylococci in patients with staphylococcal bacteremia. *Diagn Microbiol Infect Dis*. 2013 Feb;75(2):139–43.
81. Bouza E, Rojas L, Guembe M, Marín M, Anaya F, Luño J, et al. Predictive value of superficial cultures to anticipate tunneled hemodialysis catheter-related bloodstream infection. *Diagn Microbiol Infect Dis*. 2014 Mar;78(3):316–9.
82. Afshari A, Schrenzel J, Ieven M, Harbarth S. Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection--a new frontier? *Crit Care*. 2012;16(3):222.
83. Janum S, Zingg W, Classen V, Afshari A. Bench-to-bedside review: Challenges of diagnosis, care and prevention of central catheter-related bloodstream infections in children. *Crit Care*. 2013;17(4):238.
84. Pascual A, Cercenado E, Salavert M, Elías García-Sánchez J, Eiros JM, Liñares J, et al. Update on pathogenesis and diagnosis of intravascular catheter-related infections. *Enferm Infect Microbiol Clin*. 2011 Mar;29 (Suppl 4):16–21.
85. Timsit J-F, Dubois Y, Minet C, Bonadona A, Lugosi M, Ara-Somohano C, et al. New challenges in the diagnosis, management, and prevention of central venous catheter-related infections. *Semin Respir Crit Care Med*. 2011 Apr;32(2):139–50.
86. Wolf H-H, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I, et al. Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol*. 2008 Nov;87(11):863–76.
87. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. *Clin Microbiol Infect*. 2006 Jul;12(7):606–20.
88. Leonidou L, Gogos CA. Catheter-related bloodstream infections: catheter management according to pathogen. *Int J Antimicrob Agents*. 2010 Dec;36 (Suppl 2):S26–32.

89. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. *N Engl J Med.* 1977 Jun 9;296(23):1305–9.
90. Liñares J, Sitges-Serra A, Garau J, Pérez JL, Martín R. Pathogenesis of catheter sepsis: a prospective study with quantitative and semiquantitative cultures of catheter hub and segments. *J Clin Microbiol.* 1985 Mar;21(3):357–60.
91. Cleri DJ, Corrado ML, Seligman SJ. Quantitative culture of intravenous catheters and other intravascular inserts. *J Infect Dis.* 1980 Jun;141(6):781–6.
92. Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, Rapin M. Diagnosis of central venous catheter-related sepsis. Critical level of quantitative tip cultures. *Arch Intern Med.* 1987 May;147(5):873–7.
93. Sherertz RJ, Raad II, Belani A, Koo LC, Rand KH, Pickett DL, et al. Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory. *J Clin Microbiol.* 1990 Jan;28(1):76–82.
94. Erb S, Frei R, Schregenberger K, Dangel M, Nogarth D, Widmer AF. Sonication for diagnosis of catheter-related infection is not better than traditional roll-plate culture: a prospective cohort study with 975 central venous catheters. *Clin Infect Dis.* 2014 Aug 15;59(4):541–4.
95. Bouza E, Alvarado N, Alcalá L, Sánchez-Conde M, Pérez MJ, Muñoz P, et al. A prospective, randomized, and comparative study of 3 different methods for the diagnosis of intravascular catheter colonization. *Clin Infect Dis.* 2005 Apr 15;40(8):1096–100.
96. Slobbe L, El Barzouhi A, Boersma E, Rijnders BJA. Comparison of the roll plate method to the sonication method to diagnose catheter colonization and bacteremia in patients with long-term tunneled catheters: A randomized prospective study. *J Clin Microbiol.* 2009 Apr;47(4):885–8.
97. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. *J Infect Dis.* 1993 Aug;168(2):400–7.
98. Collignon PJ, Soni N, Pearson IY, Woods WP, Munro R, Sorrell TC. Is semiquantitative culture of central vein catheter tips useful in the diagnosis of catheter-associated bacteremia? *J Clin Microbiol.* 1986 Oct;24(4):532–5.
99. Dooley DP, Garcia A, Kelly JW, Longfield RN, Harrison L. Validation of catheter semiquantitative culture technique for nonstaphylococcal organisms. *J Clin Microbiol.* 1996 Feb;34(2):409–12.

100. de Cueto-López M, Del Pozo-León JL, Franco-Álvarez de Luna F, Marin-Arriaza M. [Microbiological diagnosis of medical device-associated infections]. *Enferm Infect Microbiol Clin.* 2016 Dec;34(10):655-660.
101. Douard MC, Arlet G, Longuet P, Troje C, Rouveau M, Ponscarme D, et al. Diagnosis of venous access port-related infections. *Clin Infect Dis.* 1999 Nov;29(5):1197–202.
102. Longuet P, Douard MC, Arlet G, Molina JM, Benoit C, Leport C. Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool. *Clin Infect Dis.* 2001 Jun 15;32(12):1776–83.
103. Whitman ED, Boatman AM. Comparison of diagnostic specimens and methods to evaluate infected venous access ports. *Am J Surg.* 1995 Dec;170(6):665-669; discussion 669-670.
104. Lebeaux D, Fernández-Hidalgo N, Chauhan A, Lee S, Ghigo J-M, Almirante B, et al. Management of infections related to totally implantable venous-access ports: challenges and perspectives. *Lancet Infect Dis.* 2014 Feb;14(2):146–59.
105. Bouza E, Martín-Rabadán P, Echenagusia A, Camúñez F, Rodríguez-Rosales G, Simó G, et al. Diagnosis of venous access port colonization requires cultures from multiple sites: Should guidelines be amended? *Diagn Microbiol Infect Dis.* 2014 Feb;78(2):162–7.
106. del Pozo JL, Alonso M, de la Torre M, Aguinaga A. Infections related to totally implantable venous-access ports. *Lancet Infect Dis.* 2014 Aug;14(8):676.
107. Lepainteur M, Desroches M, Bourrel AS, Aberrane S, Fihman V, L'Hériteau F, et al. Role of the central venous catheter in bloodstream infections caused by coagulase-negative staphylococci in very preterm neonates. *Pediatr Infect Dis J.* 2013 Jun;32(6):622–8.
108. Aldea-Mansilla C, García de Viedma D, Cercenado E, Martín-Rabadán P, Marín M, Bouza E. Comparison of phenotypic with genotypic procedures for confirmation of coagulase-negative *Staphylococcus* catheter-related bloodstream infections. *J Clin Microbiol.* 2006 Oct;44(10):3529–32.
109. Escribano P, Guinea J, Marcos-Zambrano L, Recio S, Peláez T, Rodríguez-Créixems M, et al. Does identification to species level provide sufficient evidence to confirm catheter-related fungemia caused by *Candida albicans*? *Med Mycol.* 2013 Oct;51(7):769–73.
110. Guembe M, Marín M, Martín-Rabadán P, Echenagusia A, Camúñez F, Rodríguez-Rosales G, et al. Use of universal 16S rRNA gene PCR as a diagnostic tool for venous access port-related bloodstream infections. *J Clin Microbiol.* 2013 Mar;51(3):799–804.

111. Weber DJ, Rutala WA. Central line-associated bloodstream infections: prevention and management. *Infect Dis Clin North Am.* 2011 Mar;25(1):77–102.
112. Safdar N, Maki DG. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. *Crit Care Med.* 2002 Dec;30(12):2632–5.
113. Guembe M, Martín-Rabadán P, Echenagusia A, Camúñez F, Rodríguez-Rosales G, Simó G, et al. Value of superficial cultures for prediction of catheter-related bloodstream infection in long-term catheters: a prospective study. *J Clin Microbiol.* 2013 Sep;51(9):3025–30.
114. Bouza E, Muñoz P, Burillo A, López-Rodríguez J, Fernández-Pérez C, Pérez MJ, et al. The challenge of anticipating catheter tip colonization in major heart surgery patients in the intensive care unit: Are surface cultures useful? *Crit Care Med.* 2005 Sep;33(9):1953–60.
115. León M, García M, Herranz MA, González V, Martínez A, Castillo F, et al. [Diagnostic value of Gram staining of peri-catheter skin and the connection in the prediction of intravascular-catheter-related bacteremia]. *Enferm Infecc Microbiol Clin.* 1998 May;16(5):214–8.
116. Fortún J, Perez-Molina JA, Asensio A, Calderón C, Casado JL, Mir N, et al. Semiquantitative culture of subcutaneous segment for conservative diagnosis of intravascular catheter-related infection. *JPEN J Parenter Enteral Nutr.* 2000 Aug;24(4):210–4.
117. Lebeaux D, Larroque B, Gellen-Dautremer J, Leflon-Guibout V, Dreyer C, Bialek S, et al. Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. *Medicine (Baltimore).* 2012 Nov;91(6):309–18.
118. Rijnders BJ, Peetermans WE, Verwaest C, Wilmer A, Van Wijngaerden E. Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: a randomized trial. *Intensive Care Med.* 2004 Jun;30(6):1073–80.
119. Lorente L, Martín MM, Vidal P, Rebollo S, Ostabal MI, Solé-Violán J, et al. Should central venous catheter be systematically removed in patients with suspected catheter related infection? *Crit Care.* 2014;18(5):564.
120. Janum S, Afshari A. Central venous catheter (CVC) removal for patients of all ages with candidaemia. *Cochrane Database Syst Rev.* 2016 Jul 11;7:CD011195.
121. Sabatier C, García X, Ferrer R, Duarte M, Colomina M, Alcaráz D, et al. Blood culture differential time to positivity enables safe catheter retention in suspected catheter-related bloodstream infection: a randomized controlled trial. *Med Intensiva.* 2015 Apr;39(3):135–41.

122. Parienti J-J, Mongardon N, Mégarbane B, Mira J-P, Kalfon P, Gros A, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site. *N Engl J Med.* 2015 Sep 24;373(13):1220–9.
123. Cook D, Randolph A, Kerneran P, Cupido C, King D, Soukup C, et al. Central venous catheter replacement strategies: a systematic review of the literature. *Crit Care Med.* 1997 Aug;25(8):1417–24.
124. Garnacho-Montero J, Aldabó-Pallás T, Palomar-Martínez M, Vallés J, Almirante B, Garcés R, et al. Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: a multicenter study. *Intensive Care Med.* 2008 Dec;34(12):2185–93.
125. Casey J, Davies J, Balshaw-Greer A, Taylor N, Crowe AV, McClelland P. Inserting tunneled hemodialysis catheters using elective guidewire exchange from nontunneled catheters: is there a greater risk of infection when compared with new-site replacement? *Hemodial Int.* 2008 Jan;12(1):52–4.
126. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. *Medicine (Baltimore).* 2002 Nov;81(6):466–79.
127. Ekkelenkamp MB, van der Bruggen T, van de Vijver DAMC, Wolfs TFW, Bonten MJM. Bacteremic complications of intravascular catheters colonized with *Staphylococcus aureus*. *Clin Infect Dis.* 2008 Jan 1;46(1):114–8.
128. Ruhe JJ, Menon A. Clinical significance of isolated *Staphylococcus aureus* central venous catheter tip cultures. *Clin Microbiol Infect.* 2006 Sep;12(9):933–6.
129. Hetem DJ, de Ruiter SC, Buiting AGM, Kluytmans JAJW, Thijssen SF, Vlaminckx BJM, et al. Preventing *Staphylococcus aureus* bacteremia and sepsis in patients with *Staphylococcus aureus* colonization of intravascular catheters: A retrospective multicenter study and meta-analysis. *Medicine (Baltimore).* 2011 Jul;90(4):284–8.
130. Muñoz P, Fernández Cruz A, Usúbillaga R, Zorzano A, Rodríguez-Créixems M, Guembe M, et al. Central venous catheter colonization with *Staphylococcus aureus* is not always an indication for antimicrobial therapy. *Clin Microbiol Infect.* 2012 Sep;18(9):877–82.
131. Guembe M, Rodríguez-Créixems M, Martín-Rabadán P, Alcalá L, Muñoz P, Bouza E. The risk of catheter-related bloodstream infection after withdrawal of colonized catheters is low. *Eur J Clin Microbiol Infect Dis.* 2014 May;33(5):729–34.
132. Pérez-Parra A, Muñoz P, Guinea J, Martín-Rabadán P, Guembe M, Bouza E. Is *Candida* colonization of central vascular catheters in non-

candidemic, non-neutropenic patients an indication for antifungals? *Intensive Care Med.* 2009 Apr;35(4):707–12.

133. López-Medrano F, Fernández-Ruiz M, Origüen J, Belarte-Tornero LC, Carazo-Medina R, Panizo-Mota F, et al. Clinical significance of *Candida* colonization of intravascular catheters in the absence of documented candidemia. *Diagn Microbiol Infect Dis.* 2012 Jun;73(2):157–61.
134. Park K-H, Kim S-H, Song EH, Jang E-Y, Lee EJ, Chong YP, et al. Development of bacteraemia or fungaemia after removal of colonized central venous catheters in patients with negative concomitant blood cultures. *Clin Microbiol Infect.* 2010 Jun;16(6):742–6.
135. Naber CK. *Staphylococcus aureus* bacteremia: epidemiology, pathophysiology, and management strategies. *Clin Infect Dis.* 2009 May 15;48 (Suppl 4):S231-237.
136. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. *Antimicrob Agents Chemother.* 2009 Oct;53(10):4069–79.
137. Yoon YK, Park DW, Sohn JW, Kim HY, Kim Y-S, Lee C-S, et al. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother.* 2014;58(1):317–24.
138. Rodríguez-Aranda A, Daskalaki M, Villar J, Sanz F, Otero JR, Chaves F. Nosocomial spread of linezolid-resistant *Staphylococcus haemolyticus* infections in an intensive care unit. *Diagn Microbiol Infect Dis.* 2009 Apr;63(4):398–402.
139. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother.* 2007 Jul;51(7):2582–6.
140. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J Clin Microbiol.* 2004 Jun;42(6):2398–402.
141. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant *Staphylococcus aureus* with a high vancomycin minimum inhibitory concentration: a case-control study. *Clin Infect Dis.* 2012 Jan 1;54(1):51–8.
142. Stryjewski ME, Szczech LA, Benjamin DK, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-

susceptible *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2007 Jan 15;44(2):190–6.

143. Kim S-H, Kim K-H, Kim H-B, Kim N-J, Kim E-C, Oh M, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother*. 2008 Jan;52(1):192–7.
144. Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible *Staphylococcus aureus* bacteremia. *BMC Infect Dis*. 2011;11:279.
145. McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible *Staphylococcus aureus* bloodstream infections among 122 hospitals. *Clin Infect Dis*. 2015 Aug 1;61(3):361–7.
146. Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillin-resistant *Staphylococcus aureus* and heterogeneously vancomycin-intermediate *S. aureus* in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. *J Antimicrob Chemother*. 2009 Jan;63(1):155–60.
147. Marco F, de la MÀria CG, Armero Y, Amat E, Soy D, Moreno A, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2008 Jul;52(7):2538–43.
148. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med*. 2006 Aug 17;355(7):653–65.
149. Gasch O, Camoëz M, Dominguez MA, Padilla B, Pintado V, Almirante B, et al. Predictive factors for mortality in patients with methicillin-resistant *Staphylococcus aureus* bloodstream infection: impact on outcome of host, microorganism and therapy. *Clin Microbiol Infect*. 2013 Nov;19(11):1049–57.
150. Chaftari A-M, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. *Int J Antimicrob Agents*. 2010 Aug;36(2):182–6.
151. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. *Clin Infect Dis*. 2009 Jan 15;48(2):203–12.

152. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for *Staphylococcus aureus* bacteraemia: pooled analysis of randomized studies. *J Antimicrob Chemother.* 2005 Nov;56(5):923–9.
153. Bouza E, Eworo A, Fernández Cruz A, Reigadas E, Rodríguez-Créixems M, Muñoz P. Catheter-related bloodstream infections caused by Gram-negative bacteria. *J Hosp Infect.* 2013 Dec;85(4):316–20.
154. Marcos M, Soriano A, Iñurrieta A, Martínez JA, Romero A, Cobos N, et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. *J Antimicrob Chemother.* 2011 Sep;66(9):2119–25.
155. Sreeramoju PV, Tolentino J, Garcia-Houchins S, Weber SG. Predictive factors for the development of central line-associated bloodstream infection due to gram-negative bacteria in intensive care unit patients after surgery. *Infect Control Hosp Epidemiol.* 2008 Jan;29(1):51–6.
156. Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, et al. Central venous catheter and *Stenotrophomonas maltophilia* bacteremia in cancer patients. *Cancer.* 2006 May 1;106(9):1967–73.
157. Bouza E, Burillo A, Guembe M. Managing intravascular catheter-related infections in heart transplant patients: how far can we apply IDSA guidelines for immunocompromised patients? *Curr Opin Infect Dis.* 2011 Aug;24(4):302–8.
158. Braun E, Hussein K, Geffen Y, Rabino G, Bar-Lavie Y, Paul M. Predominance of Gram-negative bacilli among patients with catheter-related bloodstream infections. *Clin Microbiol Infect.* 2014 Oct;20(10):O627–629.
159. Lorente L, Jiménez A, Santana M, Iribarren JL, Jiménez JJ, Martín MM, et al. Microorganisms responsible for intravascular catheter-related bloodstream infection according to the catheter site. *Crit Care Med.* 2007 Oct;35(10):2424–7.
160. Nagao M, Hotta G, Yamamoto M, Matsumura Y, Ito Y, Takakura S, et al. Predictors of *Candida* spp. as causative agents of catheter-related bloodstream infections. *Diagn Microbiol Infect Dis.* 2014 Nov;80(3):200–3.
161. Hu B, Du Z, Kang Y, Zang B, Cui W, Qin B, et al. Catheter-related *Candida* bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study. *BMC Infect Dis.* 2014;14:594.
162. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. *Kidney Int.* 1999 Mar;55(3):1081–90.
163. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol.* 1998 May;9(5):869–76.

164. Capdevila JA, Segarra A, Planes AM, Ramírez-Arellano M, Pahissa A, Piera L, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. *Nephrol Dial Transplant*. 1993;8(3):231–4.
165. Lee HR, Lee YK, Song YL, Kim SJ, Joo MH, Kim SG, et al. Treatment of catheter-related bacteremia with an antibiotic lock protocol in hemodialysis patients. *Korean J Nephrol*. 2005;24:903–11.
166. Aslam S, Vaida F, Ritter M, Mehta RL. Systematic review and meta-analysis on management of hemodialysis catheter-related bacteremia. *J Am Soc Nephrol*. 2014 Dec;25(12):2927–41.
167. Khosroshahi HT, Mahdipur H, Parkhideh S, Basmenji S, Khalilzadeh M, Tozihi M. The effectiveness of systemic antibiotic therapy with and without ethanol-locked solution in the treatment of hemodialysis-related catheter infection. *Saudi J Kidney Dis Transpl*. 2015 Jun;26(3):477–81.
168. Gibson SP, Mosquera D. Five years experience with the Quinton Permcath for vascular access. *Nephrol Dial Transplant*. 1991;6(4):269–74.
169. Almirall J, Gonzalez J, Rello J, Campistol JM, Montoliu J, Puig de la Bellacasa J, et al. Infection of hemodialysis catheters: incidence and mechanisms. *Am J Nephrol*. 1989;9(6):454–9.
170. Alexandraki I, Sullivan R, Zaiden R, Bailey C, McCarter Y, Khan A, et al. Blood culture isolates in hemodialysis vascular catheter-related bacteremia. *Am J Med Sci*. 2008 Oct;336(4):297–302.
171. Hayes WN, Tennankore K, Battistella M, Chan CT. Vascular access-related infection in nocturnal home hemodialysis. *Hemodial Int*. 2014 Apr;18(2):481–7.
172. Fernandez-Hidalgo N, Almirante B, Calleja R, Ruiz I, Planes AM, Rodriguez D, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. *J Antimicrob Chemother*. 2006 Jun;57(6):1172–80.
173. Langer JM, Cohen RM, Berns JS, Chittams J, Cooper ET, Trerotola SO. *Staphylococcus*-infected tunneled dialysis catheters: is over-the-wire exchange an appropriate management option? *Cardiovasc Intervent Radiol*. 2011 Dec;34(6):1230–5.
174. Lee S, Choe PG, Song K-H, Park S-W, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible *Staphylococcus aureus* bacteraemia? *Antimicrob Agents Chemother*. 2011 Nov;55(11):5122–6.
175. Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS. Comparison of cefazolin versus oxacillin for treatment of complicated

bacteremia caused by methicillin-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2014 Sep;58(9):5117–24.

176. Paul M, Zemer-Wassercug N, Talker O, Lisztzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive *Staphylococcus aureus* bacteraemia? *Clin Microbiol Infect*. 2011 Oct;17(10):1581–6.
177. Chang F-Y, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. *Staphylococcus aureus* bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. *Medicine (Baltimore)*. 2003 Sep;82(5):333–9.
178. Aguado JM, San-Juan R, Lalueza A, Sanz F, Rodríguez-Otero J, Gómez-González C, et al. High vancomycin MIC and complicated methicillin-susceptible *Staphylococcus aureus* bacteremia. *Emerging Infect Dis*. 2011 Jun;17(6):1099–102.
179. Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Domínguez MA, et al. Diagnosis and treatment of bacteremia and endocarditis due to *Staphylococcus aureus*. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). *Enferm Infecc Microbiol Clin*. 2015 Nov;33(9):625.e1-625.e23.
180. Chang F-Y, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of *Staphylococcus aureus* bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. *Medicine (Baltimore)*. 2003 Sep;82(5):322–32.
181. Men P, Li H-B, Zhai S-D, Zhao R-S. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness: A systematic review and meta-analysis. *PLoS ONE*. 2016;11(1):e0146224.
182. Lee C-H, Tsai C-Y, Li C-C, Chien C-C, Liu J-W. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. *J Antimicrob Chemother*. 2015 Jan;70(1):257–63.
183. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin Infect Dis*. 2008 Jan 15;46(2):193–200.
184. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteraemia treated with vancomycin. *Antimicrob Agents Chemother*. 2008 Sep;52(9):3315–20.
185. Park SY, Kwon KH, Chung J-W, Huh HJ, Chae SL. Coagulase-negative staphylococcal bacteraemia: risk factors for mortality and impact of initial

appropriate antimicrobial therapy on outcome. *Eur J Clin Microbiol Infect Dis.* 2015 Jul;34(7):1395–401.

186. Molina J, Peñuela I, Lepe JA, Gutiérrez-Pizarraya A, Gómez MJ, García-Cabrera E, et al. Mortality and hospital stay related to coagulase-negative Staphylococci bacteremia in non-critical patients. *J Infect.* 2013 Feb;66(2):155–62.
187. Olaechea PM, Alvarez-Lerma F, Palomar M, Insausti J, López-Pueyo MJ, Martínez-Pellús A, et al. [Impact of primary and intravascular catheter-related bacteremia due to coagulase-negative staphylococci in critically ill patients]. *Med Intensiva.* 2011 May;35(4):217–25.
188. Falcone M, Russo A, Pompeo ME, Vena A, Marruncheddu L, Ciccaglioni A, et al. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. *Int J Antimicrob Agents.* 2012 Jan;39(1):64–8.
189. Olaechea Astigarraga PM, Garnacho Montero J, Grau Cerrato S, Rodríguez Colomo O, Palomar Martínez M, Zaragoza Crespo R, et al. [Summary of the GEIPC-SEIMC and GTEI-SEMICYUC recommendations for the treatment of infections caused by gram positive cocci in critical patients]. *Farm Hosp.* 2007 Dec;31(6):353–69.
190. Choi S-H, Chung J-W, Lee EJ, Kim TH, Lee MS, Kang JM, et al. Incidence, characteristics, and outcomes of *Staphylococcus lugdunensis* bacteremia. *J Clin Microbiol.* 2010 Sep;48(9):3346–9.
191. Reigadas E, Rodríguez-Créixems M, Guembe M, Sánchez-Carrillo C, Martín-Rabadán P, Bouza E. Catheter-related bloodstream infection caused by *Enterococcus* spp. *Clin Microbiol Infect.* 2013 May;19(5):457–61.
192. Foo H, Chater M, Maley M, van Hal SJ. Glycopeptide use is associated with increased mortality in *Enterococcus faecalis* bacteraemia. *J Antimicrob Chemother.* 2014 Aug;69(8):2252–7.
193. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. *Antimicrob Agents Chemother.* 2014;58(2):734–9.
194. Chuang Y-C, Wang J-T, Lin H-Y, Chang S-C. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. *BMC Infect Dis.* 2014;14:687.
195. Marshall J, Piccirillo ML, Fraser VJ, Doherty JA, Warren DK. Catheter removal versus retention in the management of catheter-associated enterococcal bloodstream infections. *Can J Infect Dis Med Microbiol.* 2013;24(3):e83-87.

196. Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, et al. [Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document]. *Enferm Infect Microbiol Clin.* 2012 Jan;30(1):22.e1-22.e23.
197. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2016 Feb 15;62(4):e1-50.
198. Aguado JM, Ruiz-Camps I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. [Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. *Enferm Infect Microbiol Clin.* 2011 May;29(5):345–61.
199. Vazquez J, Reboli AC, Pappas PG, Patterson TF, Reinhardt J, Chin-Hong P, et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. *BMC Infect Dis.* 2014;14:97.
200. Bailly S, Leroy O, Montravers P, Constantin J-M, Dupont H, Guillemot D, et al. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. *Intensive Care Med.* 2015 Nov;41(11):1931–40.
201. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Lepe-Jiménez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in *Candida* spp. bloodstream infections. *J Antimicrob Chemother.* 2013 Jan;68(1):206–13.
202. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis.* 2012 Apr;54(8):1110–22.
203. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, Cecilia T, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. *Intensive Care Med.* 2014 Jun;40(6):839–45.
204. Chatzimoschou A, Katragkou A, Simitopoulou M, Antachopoulos C, Georgiadou E, Walsh TJ, et al. Activities of triazole-echinocandin combinations against *Candida* species in biofilms and as planktonic cells. *Antimicrob Agents Chemother.* 2011 May;55(5):1968–74.
205. Ramage G, Jose A, Sherry L, Lappin DF, Jones B, Williams C. Liposomal amphotericin B displays rapid dose-dependent activity against *Candida*

albicans biofilms. *Antimicrob Agents Chemother*. 2013 May;57(5):2369–71.

206. Choi HW, Shin JH, Jung SI, Park KH, Cho D, Kee SJ, et al. Species-specific differences in the susceptibilities of biofilms formed by *Candida* bloodstream isolates to echinocandin antifungals. *Antimicrob Agents Chemother*. 2007 Apr;51(4):1520–3.

207. Walraven CJ, Lee SA. Antifungal lock therapy. *Antimicrob Agents Chemother*. 2013 Jan;57(1):1–8.

208. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against *Candida albicans* biofilms. *J Antimicrob Chemother*. 2010 Feb;65(2):271–4.

209. El Helou G, Hachem R, Viola GM, El Zakhem A, Chaftari A-M, Jiang Y, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients. *Clin Infect Dis*. 2013 Mar;56(6):843–6.

210. El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections. *Lancet Infect Dis*. 2013 Feb;13(2):166–74.

211. Raad II, Vartivarian S, Khan A, Bodey GP. Catheter-related infections caused by the *Mycobacterium fortuitum* complex: 15 cases and review. *Rev Infect Dis*. 1991 Dec;13(6):1120–5.

212. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007 Feb 15;175(4):367–416.

213. Brown-Elliott BA, Wallace RJ, Petti CA, Mann LB, McGlasson M, Chihara S, et al. *Mycobacterium neoaurum* and *Mycobacterium bacteremicum* sp. nov. as causes of mycobacteremia. *J Clin Microbiol*. 2010 Dec;48(12):4377–85.

214. Schrenzel J, Harbarth S, Schockmel G, Genné D, Bregenzer T, Flueckiger U, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. *Clin Infect Dis*. 2004 Nov 1;39(9):1285–92.

215. Rodriguez-Pardo D, Pigrau C, Campany D, Diaz-Brito V, Morata L, de Diego IC, et al. Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with gram-positive infection: the SEQUENCE cohort study. *Eur J Clin Microbiol Infect Dis*. 2016 Aug;35(8):1269–76.

216. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med*. 2002 Dec 19;347(25):2020–9.

217. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. *N Engl J Med.* 2007 Jun 14;356(24):2472–82.
218. Kuse E-R, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet.* 2007 May 5;369(9572):1519–27.
219. Niyyar VD, Lok CE. Pros and cons of catheter lock solutions. *Curr Opin Nephrol Hypertens.* 2013 Nov;22(6):669–74.
220. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. *J Antimicrob Chemother.* 2005 Jan;55(1):90–4.
221. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. *Kidney Int.* 2002 Mar;61(3):1136–42.
222. Fernández-Hidalgo N, Almirante B. Antibiotic-lock therapy: a clinical viewpoint. *Expert Rev Anti Infect Ther.* 2014 Jan;12(1):117–29.
223. Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. *Infect Drug Resist.* 2014;7:343–63.
224. Bustos C, Aguinaga A, Carmona-Torre F, Del Pozo JL. Long-term catheterization: current approaches in the diagnosis and treatment of port-related infections. *Infect Drug Resist.* 2014;7:25–35.
225. del Pozo JL. Role of antibiotic lock therapy for the treatment of catheter-related bloodstream infections. *Int J Artif Organs.* 2009 Sep;32(9):678–88.
226. Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. *Am J Health Syst Pharm.* 2010 Jul 15;67(14):1195–8.
227. Battistella M, Walker S, Law S, Lok C. Antibiotic lock: in vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37 degrees C. *Hemodial Int.* 2009 Jul;13(3):322–8.
228. Fortún J, Grill F, Martín-Dávila P, Blázquez J, Tato M, Sánchez-Corral J, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. *J Antimicrob Chemother.* 2006 Oct;58(4):816–21.
229. Bookstaver PB, Rokas KEE, Norris LB, Edwards JM, Sherertz RJ. Stability and compatibility of antimicrobial lock solutions. *Am J Health Syst Pharm.* 2013 Dec 15;70(24):2185–98.

230. Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. *J Antimicrob Chemother*. 2003 Apr;51(4):849–55.
231. Yılmaz H, Mutlu Yılmaz E, Esen S, Sünbül M, Leblebicioğlu H. [Treatment of hemodialysis catheter-associated bacteremia due to methicillin-resistant *Staphylococcus aureus* by daptomycin lock method]. *Mikrobiyol Bul*. 2012 Jul;46(3):470–4.
232. Estes R, Theusch J, Beck A, Pitrak D, Mullane KM. Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant *Staphylococcus aureus* isolates embedded in biofilm. *Antimicrob Agents Chemother*. 2013 Apr;57(4):1998–2000.
233. Del Pozo JL, Rodil R, Aguinaga A, Yuste JR, Bustos C, Montero A, et al. Daptomycin lock therapy for grampositive long-term catheter-related bloodstream infections. *Int J Clin Pract*. 2012 Mar;66(3):305–8.
234. Funalleras G, Fernández-Hidalgo N, Borrego A, Almirante B, Planes AM, Rodríguez D, et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. *Clin Infect Dis*. 2011 Nov;53(9):e129-132.
235. Maya ID, Carlton D, Estrada E, Allon M. Treatment of dialysis catheter-related *Staphylococcus aureus* bacteremia with an antibiotic lock: a quality improvement report. *Am J Kidney Dis*. 2007 Aug;50(2):289–95.
236. Santarpia L, Pasanisi F, Alfonsi L, Violante G, Tiseo D, De Simone G, et al. Prevention and treatment of implanted central venous catheter (CVC) - related sepsis: a report after six years of home parenteral nutrition (HPN). *Clin Nutr*. 2002 Jun;21(3):207–11.
237. Domingo P, Fontanet A, Sánchez F, Allende L, Vazquez G. Morbidity associated with long-term use of totally implantable ports in patients with AIDS. *Clin Infect Dis*. 1999 Aug;29(2):346–51.
238. Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. *Clin Infect Dis*. 1995 Nov;21(5):1286–8.
239. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. *JPEN J Parenter Enteral Nutr*. 1988 Apr;12(2):185–9.
240. Moore CL, Besarab A, Ajluni M, Soi V, Peterson EL, Johnson LE, et al. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. *Clin J Am Soc Nephrol*. 2014 Jul;9(7):1232–9.

241. Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. *Nephrol Dial Transplant*. 2004 May;19(5):1237–44.
242. Vardhan A, Davies J, Daryanani I, Crowe A, McClelland P. Treatment of haemodialysis catheter-related infections. *Nephrol Dial Transplant*. 2002 Jun;17(6):1149–50.
243. Bailey E, Berry N, Cheesbrough JS. Antimicrobial lock therapy for catheter-related bacteraemia among patients on maintenance haemodialysis. *J Antimicrob Chemother*. 2002 Oct;50(4):615–7.
244. Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. *Diagn Microbiol Infect Dis*. 2009 Feb;63(2):208–12.
245. Joshi AJ, Hart PD. Antibiotic catheter locks in the treatment of tunneled hemodialysis catheter-related blood stream infection. *Semin Dial*. 2013 Apr;26(2):223–6.
246. Del Pozo JL, García Cenoz M, Hernández S, Martínez A, Serrera A, Aguinaga A, et al. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis. *Int J Antimicrob Agents*. 2009 Nov;34(5):482–5.
247. Schoot RA, van Ommen CH, Stijnen T, Tissing WJE, Michiels E, Abbink FCH, et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial. *Eur J Cancer*. 2015 Sep;51(14):2031–8.
248. Broom JK, Krishnasamy R, Hawley CM, Playford EG, Johnson DW. A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients--the HEALTHY-CATH trial. *BMC Nephrol*. 2012;13:146.
249. Slobbe L, Doorduijn JK, Lugtenburg PJ, El Barzouhi A, Boersma E, van Leeuwen WB, et al. Prevention of catheter-related bacteraemia with a daily ethanol lock in patients with tunneled catheters: a randomized, placebo-controlled trial. *PLoS ONE*. 2010;5(5):e10840.
250. Pérez-Granda MJ, Barrio JM, Muñoz P, Hortal J, Rincón C, Rabadán PM, et al. Ethanol lock therapy (E-Lock) in the prevention of catheter-related bloodstream infections (CR-BSI) after major heart surgery (MHS): a randomized clinical trial. *PLoS ONE*. 2014;9(3):e91838.
251. Kubiak DW, Gilmore ET, Buckley MW, Lynch R, Marty FM, Koo S. Adjunctive management of central line-associated bloodstream infections with 70% ethanol-lock therapy. *J Antimicrob Chemother*. 2014 Jun;69(6):1665–8.

252. McGrath EJ, Salloum R, Chen X, Jiang Y, Boldt-MacDonald K, Becker C, et al. Short-dwell ethanol lock therapy in children is associated with increased clearance of central line-associated bloodstream infections. *Clin Pediatr (Phila)*. 2011 Oct;50(10):943–51.
253. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. *Int J Antimicrob Agents*. 2004 Nov;24(5):491–5.
254. Reitzel RA, Rosenblatt J, Hirsh-Ginsberg C, Murray K, Chaftari A-M, Hachem R, et al. In vitro assessment of the antimicrobial efficacy of optimized nitroglycerin-citrate-ethanol as a nonantibiotic, antimicrobial catheter lock solution for prevention of central line-associated bloodstream infections. *Antimicrob Agents Chemother*. 2016 Sep;60(9):5175–81.
255. Dibb MJ, Abraham A, Chadwick PR, Shaffer JL, Teubner A, Carlson GL, et al. Central venous catheter salvage in home parenteral nutrition catheter-related bloodstream infections: Long-term safety and efficacy data. *JPEN J Parenter Enteral Nutr*. 2016 Jul;40(5):699–704.
256. Wintenberger C, Epaulard O, Hincky-Vitrat V, Brion JP, Recule C, François P, et al. Outcome of central venous catheter-related bacteraemia according to compliance with guidelines: experience with 91 episodes. *J Hosp Infect*. 2012 Mar;80(3):245–51.
257. Capdevila JA, Segarra A, Planes AM, Gasser I, Gavaldà J, Valverde PR, et al. Long-term follow-up of patients with catheter-related bacteremia treated without catheter removal. *Clin Microbiol Infect*. 1998 Aug 1;4(8):472–6.
258. ebpg-vascular-access-  
12\_management\_of\_the\_infected\_vascular\_access.pdf [Internet]. Available from: [http://www.vascularaccesssociety.com/resources/media/Guidelines/12\\_management\\_of\\_the\\_infected\\_vascular\\_access.pdf](http://www.vascularaccesssociety.com/resources/media/Guidelines/12_management_of_the_infected_vascular_access.pdf)
259. Mayhall CG. Diagnosis and management of infections of implantable devices used for prolonged venous access. *Curr Clin Top Infect Dis*. 1992;12:83–110.
260. Ferrer C, Almirante B. [Venous catheter-related infections]. *Enferm Infecc Microbiol Clin*. 2014 Feb;32(2):115–24.
261. Pittiruti M, Hamilton H, Biffi R, MacFie J, Pertkiewicz M, ESPEN. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). *Clin Nutr*. 2009 Aug;28(4):365–77.
262. 93500NKF\_CPG\_Cover-R1.indd - 12-50-0210\_jag\_dcp\_guidelines-hd\_oct06\_sectiona\_ofc.pdf [Internet]. Available from:

[https://www.kidney.org/sites/default/files/docs/12-50-0210\\_jag\\_dcp\\_guidelines-hd\\_oct06\\_sectiona\\_ofc.pdf](https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-hd_oct06_sectiona_ofc.pdf)

263. Meek ME. Diagnosis and treatment of central venous access-associated infections. *Tech Vasc Interv Radiol.* 2011 Dec;14(4):212–6.
264. Segarra-Newham M, Martin-Cooper EM. Antibiotic lock technique: A review of the literature. *Ann Pharmacother.* 2005 Feb;39(2):311–8.
265. Fowler VG, Justice A, Moore C, Benjamin DK, Woods CW, Campbell S, et al. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteraemia. *Clin Infect Dis.* 2005 Mar 1;40(5):695–703.
266. Chong YP, Moon SM, Bang K-M, Park HJ, Park S-Y, Kim M-N, et al. Treatment duration for uncomplicated *Staphylococcus aureus* bacteraemia to prevent relapse: Analysis of a prospective observational cohort study. *Antimicrob Agents Chemother.* 2013 Mar;57(3):1150–6.
267. Fowler VG, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated *Staphylococcus aureus* bacteraemia. *Arch Intern Med.* 2003 Sep 22;163(17):2066–72.
268. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, et al. Persistence in *Staphylococcus aureus* bacteraemia: incidence, characteristics of patients and outcome. *Scand J Infect Dis.* 2006;38(1):7–14.
269. Kim S-H, Yoon YK, Kim MJ, Sohn JW. Clinical impact of time to positivity for *Candida* species on mortality in patients with candidaemia. *J Antimicrob Chemother.* 2013 Dec;68(12):2890–7.
270. Holland TL, Arnold C, Fowler VG. Clinical management of *Staphylococcus aureus* bacteraemia: a review. *JAMA.* 2014 Oct 1;312(13):1330–41.
271. Fowler VG, Li J, Corey GR, Boley J, Marr KA, Gopal AK, et al. Role of echocardiography in evaluation of patients with *Staphylococcus aureus* bacteraemia: experience in 103 patients. *J Am Coll Cardiol.* 1997 Oct;30(4):1072–8.
272. Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of *Staphylococcus aureus* bacteraemia. *J Heart Valve Dis.* 2005 Jan;14(1):23–8.
273. Incan A, Hair C, Purnell P, O'Brien DP, Cheng AC, Appelbe A, et al. *Staphylococcus aureus* bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. *Eur J Clin Microbiol Infect Dis.* 2013 Aug;32(8):1003–8.
274. Van Hal SJ, Mathur G, Kelly J, Aronis C, Cranney GB, Jones PD. The role of transthoracic echocardiography in excluding left sided infective

endocarditis in *Staphylococcus aureus* bacteraemia. *J Infect.* 2005 Oct;51(3):218–21.

275. Khatib R, Sharma M. Echocardiography is dispensable in uncomplicated *Staphylococcus aureus* bacteremia. *Medicine (Baltimore)*. 2013 May;92(3):182–8.

276. Kaasch AJ, Fowler VG, Rieg S, Peyerl-Hoffmann G, Birkholz H, Hellmich M, et al. Use of a simple criteria set for guiding echocardiography in nosocomial *Staphylococcus aureus* bacteremia. *Clin Infect Dis.* 2011 Jul 1;53(1):1–9.

277. Rasmussen RV, Høst U, Arpi M, Hassager C, Johansen HK, Korup E, et al. Prevalence of infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: the value of screening with echocardiography. *Eur J Echocardiogr.* 2011 Jun;12(6):414–20.

278. Joseph JP, Meddows TR, Webster DP, Newton JD, Myerson SG, Prendergast B, et al. Prioritizing echocardiography in *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother.* 2013 Feb;68(2):444–9.

279. Buitron de la Vega P, Tandon P, Qureshi W, Nasr Y, Jayaprakash R, Arshad S, et al. Simplified risk stratification criteria for identification of patients with MRSA bacteremia at low risk of infective endocarditis: Implications for avoiding routine transesophageal echocardiography in MRSA bacteremia. *Eur J Clin Microbiol Infect Dis.* 2016 Feb;35(2):261–8.

280. Bouza E, Kestler M, Beca T, Mariscal G, Rodríguez-Créixems M, Bermejo J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. *Clin Infect Dis.* 2015 Feb 15;60(4):528–35.

281. Fernández-Cruz A, Cruz Menárguez M, Muñoz P, Pedromingo M, Peláez T, Solís J, et al. The search for endocarditis in patients with candidemia: A systematic recommendation for echocardiography? A prospective cohort. *Eur J Clin Microbiol Infect Dis.* 2015 Aug;34(8):1543–9.

282. Crowley AL, Peterson GE, Benjamin DK, Rimmer SH, Todd C, Cabell CH, et al. Venous thrombosis in patients with short- and long-term central venous catheter-associated *Staphylococcus aureus* bacteremia. *Crit Care Med.* 2008 Feb;36(2):385–90.

283. van Rooden CJ, Schippers EF, Barge RMY, Rosendaal FR, Guiot HFL, van der Meer FJM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. *J Clin Oncol.* 2005 Apr 20;23(12):2655–60.

284. Picardi M, Pagliuca S, Chiurazzi F, Iula D, Catania M, Rossano F, et al. Early ultrasonographic finding of septic thrombophlebitis is the main indicator of central venous catheter removal to reduce infection-related mortality in neutropenic patients with bloodstream infection. *Ann Oncol.* 2012 Aug;23(8):2122–8.

285. Falagas ME, Vardakas KZ, Athanasiou S. Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: A systematic review. *Eur J Pharmacol.* 2007 Feb 28;557(2-3):93-8.
286. Kniemeyer HW, Grabitz K, Buhl R, Wüst HJ, Sandmann W. Surgical treatment of septic deep venous thrombosis. *Surgery.* 1995 Jul;118(1):49-53.
287. Volkow P, Cornejo-Juárez P, Arizpe-Bravo AB, García-Méndez J, Baltazarés-Lipp E, Pérez-Padilla R. Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials. *Thromb J.* 2005 Aug 22;3:11.
288. Theodorou VP, Papaioannou VE, Tripsianis GA, Panopoulou MK, Christophoridis EK, Kouliatsis GA, et al. Procalcitonin and procalcitonin Kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. *BMC Infect Dis.* 2012;12:247.
289. Simoné G, Piroth L, Lakkis Z, Rat P, Heyd B, Ortega-Deballon P. Delay before implanting a port-a-cath after removing the previous one because of infection. *Med Mal Infect.* 2014 Jul;44(7):315-20.

**Table 1** Strength of recommendation and quality of evidence

| Category/Grading<br>strength of<br>recommendations | Definition  |
|--|---|
| <b>A</b>   | Strongly supports a recommendation for use  |
| <b>B</b>   | Moderately supports a recommendation for use  |
| <b>C</b>   | Marginally supports a recommendation for use  |
| <b>D</b>   | Supports a recommendation against use   |
| Quality of evidence                                |   |
| <b>I</b>   | Evidence from at least one properly designed randomized, controlled trial   |
| <b>II</b>  | Evidence from at least one well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from 1 center); from multiple time series; or from dramatic results of uncontrolled experiments |
| <b>III</b>   | Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies   |

**Table 2** Summary of main diagnostic methods for catheter-related bloodstream infections

|   | <b>Criteria for positivity</b> | <b>Interpretation</b>   | <b>Comments</b>   | <b>Recommendation</b> |
|---|--------------------------------|---|---|-----------------------|
| <b>Diagnosis without catheter withdrawal</b>                            |                                |   |   |                       |
| Paired quantitative blood cultures                                      | Ratio $\geq 3:1$               | Both sets are positive for the same microorganism and the set obtained through the catheter has $\geq 3:1$ fold-higher colony count than the peripheral culture | Sensitivity $\approx 79\%$<br>Specificity $\approx 99\%$<br>Labor intensive and expensive   | A-II                  |
| Paired blood cultures for differential time to positivity (DTP)         | $\geq 120$ minutes             | Both sets are positive for the same microorganism and the set obtained through the catheter becomes positive $\geq 120$ minutes earlier                         | Sensitivity: 72% to 96%<br>Specificity: 90% to 95%<br>Less specificity for long-term catheters<br>The interpretation of DTP should take into account adherence to the technical procedure and the type of microorganism | A-II                  |
| Endoluminal brushing  | $>100$ CFU                     | Indicative of CRBSI   | Sensitivity: 95% to 100%<br>Specificity: 84% to 89%<br>It may underestimate CRBSI in short-term catheters<br>Risk of pathogen dissemination and thrombotic complications  | C-III                 |
| Superficial cultures (semiquantitative cultures of skin surrounding the | $\geq 15$ CFU per plate        | Indicative of CRBSI   | Sensitivity: 78%<br>Specificity: 92%<br>Must be combined with peripheral blood culture  | B-II                  |

|  |  |  |   |      |
|--|--|--|---|------|
| portal entry and catheter hubs)  |  |  |   |      |
| Gram stain-acridine orange leukocyte cytopsin of catheter blood                | Presence of any microorganisms in a minimum of 100 high-powered fields | Indicative of CRBSI  | Sensitivity: $\approx$ 79%<br>Specificity: $\approx$ 87%<br>The technique is simple and rapid, but requires cytopsin technology | B-II |
| <b>Diagnosis with catheter withdrawal</b>                                      |  |  |   |      |
| Semiquantitative catheter culture  | $\geq 15$ CFU  | The same microorganism in at least one percutaneous blood culture and catheter tip culture | Sensitivity $\approx$ 84%<br>Specificity $\approx$ 86%<br>This method mainly detects colonization on the external surface       | A-II |
| Quantitative catheter segment culture (vortexing or flushing internal surface) | $\geq 10^3$ CFU  | The same microorganism in at least one percutaneous blood culture and catheter tip culture | Sensitivity $\approx$ 83%<br>Specificity $\approx$ 91%<br>All quantitative methods are time consuming                           | A-II |
| Quantitative catheter segment culture (sonication)                             | $\geq 10^2$ CFU  | The same microorganism in at least one percutaneous blood culture and catheter tip culture | Sensitivity $\approx$ 83%<br>Specificity $\approx$ 91%<br>All quantitative methods are time consuming                           | A-II |

**Table 4** Indications for catheter removal in patients with CRBSI

|   |
|---|
| CRBSI presenting with septic shock  |
| CRBSI caused by certain pathogens: <i>S. aureus</i> , non-fermenting Gram-negative bacilli, <i>Candida</i> spp. or <i>Mycobacterium</i> |
| Metastatic complications (endocarditis, thrombophlebitis or septic pulmonary embolism)  |
| Bacteremia (or candidemia) persisting after 72 h of adequate treatment  |
| Pus is observed at the insertion site   |
| Signs of infection at the subcutaneous tunnel   |
| No possibility of antibiotic lock therapy   |

**Table 3** The main antimicrobial drug and dosage regimens that should be used for catheter-related infections

| Antimicrobial           | Dosage   |
|-------------------------|--|
| <b>Antibacterials</b>   |  |
| Amikacin                | Loading dose: 25-30 mg/kg IV, followed by 15-20 mg/kg/d IV |
| Amoxicillin-clavulanate | 2 g/200-500 mg every 6-8 h IV                              |
| Ampicillin              | 2 g every 6-8 h IV   |
| Aztreonam               | 1-2 g/6-8 h IV   |
| Cefazolin               | 2 g every 8 h IV   |
| Cefepime                | 2 g/8-12 h IV  |
| Ceftaroline             | 600 mg/12h IV  |
| Ceftazidime             | 2 g/8-12h IV   |
| Ceftriaxone             | 1 g every 12 h   |
| Cefotaxime              | 1-2 g/6-8 h IV   |
| Ciprofloxacin           | 500 mg/12h IV VO   |
| Cloxacillin             | 2 g every 4 h IV   |
| Colistin                | 7-9 MU load, then 4.5 MU every 12 h IV                     |
| Dalbavancin             | 1,000 mg IV, 500 mg IV one week apart                      |
| Daptomycin              | 8-10 mg/kg/d IV  |
| Ertapenem               | 1 g every 24 h IV  |
| Fosfomycin              | 4 g/6-8 h IV   |
| Gentamicin              | 5-7 mg/kg/d IV   |
| Imipenem-cilastatin     | 500 mg every 6 h IV  |
| Levofloxacin            | 750 mg daily   |
| Linezolid               | 600 mg every 12 h  |

|                          |   |
|--------------------------|---|
| Meropenem                | 1 g every 8 h IV  |
| Piperacillin-tazobactam  | 4/0.5 g every 6–8 h   |
| SMX-TMP                  | 160–800 mg bid 5–10 mg/kg/day of TMP  |
| Tedizolid                | 200 mg/d  |
| Teicoplanin              | 6 mg/kg/12 h (3 doses), 6 mg/kg/d IV  |
| Tobramycin               | 5–7 mg/kg/d IV  |
| Vancomycin               | Loading dose: 25–30 mg/kg IV, then 15–20 mg/kg/8–12h IV   |
| <b>Antifungals</b>       |   |
| Anidulafungin            | 200 mg loading dose, 100 mg/d IV  |
| Caspofungin              | 70 mg loading dose, 50 mg/k/d   |
| Fluconazole              | 800 mg loading dose, then 400 mg daily  |
| Liposomal amphotericin B | 3–5 mg/kg/d   |
| Micafungin               | 100 mg/d IV   |
| Voriconazole             | 400 mg bid × 2 doses, then 200 mg every 12 h 6 mg/kg IV every 12 h for 2 doses, followed by 4 mg/kg IV every 12 h |

Note that doses of the drugs are not adjusted for renal or hepatic function.

**Table 5** Lock solutions described in the literature with potential use in clinical practice

| Microorganism                       | Antimicrobial            | Concentration | Notes  |
|-------------------------------------|--------------------------|---------------|--|
| Staphylococci <sup>1</sup>          | Daptomycin               | 5 mg/ml       | Dilute in Ringer's lactate solution (with calcium) |
|                                     | Vancomycin               | 2 mg/ml       | Incompatible with heparin > 5 mg/ml                |
|                                     | Teicoplanin              | 10 mg/ml      |  |
| Enterococci <sup>2</sup>            | Vancomycin + Gentamycin  | Both 2 mg/ml  |  |
| Gram-negative bacilli <sup>3</sup>  | Levofloxacin             | 5 mg/ml       | Precipitates with heparin                          |
|                                     | Ciprofloxacin            | 2 mg/ml       | Precipitates with heparin                          |
|                                     | Amikacin                 | 2-10 mg/ml    |  |
|                                     | Piperacillin-tazobactan  | 10 mg/ml      |  |
| <i>Candida</i> species <sup>4</sup> | Echinocandins            | 5 mg/ml       |  |
|                                     | Liposomal amphotericin B | 1-5 mg/ml     |  |

This table is not intended to be an exhaustive list. Since there are no clinical trials using levels of evidence, it reflects only the opinion of experts. Although there is no scientific evidence to make recommendations regarding optimal time duration and replacement of lock solutions, we recommend extending it for 14 days, and also drawing a blood culture through all catheter lumens 72 hours after completion of therapy. We also remind users that antimicrobial lock therapy is necessary but not sufficient. Any antimicrobial lock therapy must be accompanied by a systemic antibiotic treatment that will last over time, depending on the pathogen involved.

<sup>1</sup> A conservative treatment is recommended only in the case of coagulase-negative staphylococci. Catheter removal is recommended if *S. aureus* is involved.

<sup>2</sup> There is insufficient experience to recommend conservative treatment. However, if the patient is stable and bacteremia is uncomplicated, a conservative treatment may be considered.

<sup>3</sup> In the case of *Pseudomonas aeruginosa* and other non-fermenting Gram-negative bacilli (*Acinetobacter* spp, *Stenotrophomonas* spp and so on), there is no clear recommendation for a conservative treatment.

<sup>4</sup> In the case of catheter-related candidemia, it is recommended to remove the catheter. If it is not possible to withdraw it, or withdrawal is postponed, the catheter should be locked.


**Table 6** Preparation of the most common antibiotic solutions for lock therapy

|  |  |
|--|--|
|  |  |
| <b>Vancomycin 2,000 mg/l plus sodium heparin 20 IU/ml</b>    | 250 ml of 0.9% saline or 5% glucose<br>+<br>500 mg of vancomycin<br>+<br>5 ml of 1% sodium heparin (1 ml heparin = 1,000 IU)   |
| <b>Teicoplanin 10,000 mg/l plus sodium heparin 125 IU/ml</b> | 1. Reconstitute 400 mg of teicoplanin with 3 ml sterile water for injection<br>2. Remove 18 ml from a bag of 50 ml of 0.9% saline<br>3. Add 3 ml of reconstituted teicoplanin to saline bag<br>4. Add 5 ml of 1% sodium heparin to saline bag                      |
| <b>Daptomycin 5,000 mg/l plus sodium heparin 100 IU/ml</b>   | 1. Reconstitute 350 mg of daptomycin with 7ml of sterile water for injection<br>2. With a 1 ml syringe, take 1 ml of reconstituted daptomycin<br>3. With the same syringe, take 1 ml of 1% sodium heparin<br>4. With the same syringe, take 8 ml of Ringer lactate |
| <b>Ciprofloxacin 2,000 mg/l plus sodium heparin 20 IU/ml</b> | 1. Add 4 ml of 1% sodium heparin in a bag of 400 mg of ciprofloxacin<br>2. Stir for a minute before taking the required amount of solution   |
| <b>Amikacin 2,000 mg/l plus sodium heparin 20 IU/ml</b>      | 250 ml of 0.9% saline or 5% glucose<br>+<br>500 mg of amikacin<br>+<br>5 ml of 1% sodium heparin   |

**Figure 1. Approach to the management of a patient with suspicion of CRBSI.**

- (1) Vancomycin (alternative daptomycin; see text for specific recommendations for this agent) plus antibiotic therapy to cover gramnegative bacilli if: the femoral catheter is in place, the focus of Gram-negative infection is known, with a high index of colonization by Gram-negative bacilli or prolonged admission in ICU. As the patient is clinically stable, consider antifungal therapy (fluconazole) in patients with total parenteral nutrition, prolonged use of broad-spectrum antibiotics, malignancy, femoral catheterization, colonization due to *Candida* species at multiple sites or previous anti-anaerobic therapy.
- (2) Semi-quantitative or quantitative tip culture.
- (3) Catheter can be maintained only in patients without septic shock secondary to CRBSI, without intravascular devices, and if the culprit pathogen is a CoNS (except *Staphylococcus lugdunensis*) or a Gram-negative bacilli if the isolate is susceptible to antibiotics that are available for ALT. See Figure 2 for management.
- (4) See text and Figure 2 for choosing targeted treatment, duration of therapy, and need for echocardiography.
- (5) Vancomycin (alternative daptomycin; see text for specific recommendations of this agent) plus antibiotic therapy to cover gramnegative bacilli plus an antifungal agent in patients with septic shock or in other patients if: total parenteral nutrition, prolonged use of broad-spectrum antibiotics, malignancy, femoral catheterization, colonization due to *Candida* species at multiple sites or intense previous anti-anaerobic therapy. Echinocandins, or liposomal amphotericin B as an alternative should be used only in patients with septic shock. Fluconazole is the drug of choice for the remainder of situations, except in patients colonized by fluconazole-resistant *Candida* spp. Patients with suppuration at the insertion site but without the other conditions should not receive antibiotic therapy active against Gram-negative bacilli and antifungal agents.

DTP: differential time to positivity; QBC: quantitative blood culture.



**Figure 2. Approach to the treatment of a patient with confirmed CRBSI.**

- (1) With the exception of *Staphylococcus lugdunensis*, which should be managed as for *Staphylococcus aureus*.
- (2) Catheter must be removed in patients with septic shock secondary to CRBSI or in patients with intravascular devices.
- (3) In patients with intravascular devices, foreign bodies (such as articular prostheses) or in whom markers of inflammation persist after catheter removal therapy, antibiotic therapy for 10–14 days is recommended.
- (4) Cloxacillin or cefazolin are the alternatives for methicillin-susceptible strains. Optimal trough levels of vancomycin for CoNS are not defined.
- (5) Echocardiography should be done in patients with valvular diseases or in case of persistent bacteremia despite appropriate therapy.
- (6) Complicated episodes require longer courses of treatment (4-6 weeks).
- (7) Trough levels of vancomycin should be 15-20 mg/l.
- (8) Daptomycin is preferred for isolates with MIC for vancomycin > 1.5 mg/l.
- (9) Combined therapy with an aminoglycoside is discouraged for *Enterococcus* spp. CRBSI.
- (10) Optimal trough levels of vancomycin for *Enterococcus* spp. CRBSI are not defined.
- (11) Only in immunocompetent patients without septic shock and when the isolate is susceptible to antibiotics that are available for ALT.
- (12) If metastatic complications have been ruled out.
- (13) De-escalation from an echinocandin or a lipid formulation of amphotericin B to fluconazole is highly recommended in patients with isolates susceptible to fluconazole, are clinically stable and the catheter has been removed.

## Confirmed CRBSI

Coagulase-Negative  
*Staphylococcus*

*Staphylococcus*  
*aureus*

*Enterococcus* spp.

Gram-negative  
bacilli

*Candida* spp.

- CoNS (1)
- Consider catheter removal (if not done) (2)
- Antimicrobial therapy for 5 days (3)
- Vancomycin in the first option (4)
- Echocardiography is not mandatory (5)
- Remove catheter if *S. lugdunensis* is isolated
- **Catheter retained**
  - Antimicrobial therapy for 10-14 days
  - Vancomycin in the first option (4)
  - ALT with vancomycin for 10-14 days
  - Echocardiography is not mandatory (5)

- Removal of the catheter is mandatory
- Antimicrobial therapy for 14 days (6)
- Cloxacillin or cefazolin are the alternatives for MSSA
- Vancomycin or daptomycin are the alternatives for MRSA (7) (8)
- Echocardiography is mandatory

- Removal of the catheter is mandatory
- Antimicrobial therapy for 7-14 days
- Ampicillin is the drug of choice for susceptible strains (9)
- Vancomycin is the alternative for strains resistant to ampicillin (10)
- Echocardiography is mandatory

- Remove the catheter (if not done) (2)
- Antimicrobial therapy for at least 7 days (3)
- Antimicrobial therapy must be chosen based on the susceptibility results
- Echocardiography is not mandatory (5)
- **Catheter retained** (11)
  - Antimicrobial therapy for 10-14 days
  - Antimicrobial therapy must be chosen based on the susceptibility results
  - ALT for 10-14 days
  - Echocardiography is not mandatory (5)

- Removal of the catheter is mandatory
- Antifungal therapy for 14 days after the first negative blood culture (12)
- Targeted antifungal therapy must be chosen based on the susceptibility results (13)
- Echocardiography is mandatory

## **FIGURE 2. Approach to the treatment of a patient with confirmed CRBSI.**

- (1) With the exception of *Staphylococcus lugdunensis*, which should be managed as for *S. aureus*.
- (2) Catheter must be removed in patients with septic shock secondary to CRBSI or in patients with intravascular devices,
- (3) In patients with intravascular devices, foreign bodies (such as articular prostheses) or in whom markers of inflammation persist after catheter removal therapy, antibiotic therapy for 10–14 days is recommended.
- (4) Cloxacillin or cefazolin are the alternatives for methicillin-susceptible strains. Optimal trough levels of vancomycin for CoNS are not defined.
- (5) Echocardiography should be done in patients with valvular diseases or in case of persistent bacteremia despite appropriate therapy.
- (6) Complicated episodes require longer courses of treatment (4-6 weeks).
- (7) Trough levels of vancomycin should be 15-20 mg/L
- (8) Daptomycin is preferred for isolates with MIC for vancomycin > 1.5 mg/L.
- (9) Combined therapy with an aminoglycoside is discouraged for *Enterococcus* spp. CRBSI.
- (10) Optimal trough levels of vancomycin for *Enterococcus* spp. CRBSI are not defined.
- (11) Only in immunocompetent patients without septic shock and when the isolate is susceptible to antibiotics that are available for ALT.
- (12) If metastatic complications have been ruled out.
- (13) De-escalation from an echinocandin or a lipid formulation of amphotericin B to fluconazole is highly recommended in patients with isolates susceptible to fluconazole, are clinically stable and the catheter has been removed.